24

PCT

(51) International Patent Classification 6 : C12N 5/10, A61K 48/00 // C07K 14/705	A2	(11) International Publication Number: **WO 99/61589** (43) International Publication Date: 2 December 1999 (02.12.99)

(21) International Application Number: PCT/US99/11825

(22) International Filing Date: 27 May 1999 (27.05.99)

(30) Priority Data:
60/086,988   28 May 1998 (28.05.98)   US

(63) Related by Continuation (CON) or Continuation-in-Part
(CIP) to Earlier Application
US   60/086,988 (CIP)
Filed on   28 May 1998 (28.05.98)

(71) Applicant *(for all designated States except US)*: ST. JUDE CHILDREN'S RESEARCH HOSPITAL [US/US]; 332 North Lauderdale Street, Memphis, TN 38105-2794 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SORRENTINO, Brian [US/US]; 6590 Quail Point Circle North, Memphis, TN 38103 (US). BUNTING, Kevin [US/US]; 99 North Main #1112, Memphis, TN 38120 (US).

(74) Agents: DAVIS, Michael, D. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: EXPANSION OF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH MDR-1 AND METHODS OF USE THEREOF

(57) Abstract

The present invention includes methods of performing *ex vivo* expansion of gene–modified hematopoietic stem cells which are useful for many applications involving bone marrow transplantation and *ex vivo* gene therapy. The present invention further includes the gene–modified hematopoietic stem cells that are used and produced by such methods. Such gene–modified hematopoietic stem cells can also contain a second heterologous gene. In addition, the present invention also includes methods of engrafting the gene–modified hematopoieteic stem cells of the present invention into animals, including for *ex vivo* gene therapy and for reconstitution of hematopoieteic cells in ablated mammals.

EXPANSION OF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH MDR-1 AND METHODS OF USE THEREOF

RESEARCH SUPPORT

FIELD OF THE INVENTION

10   The present invention concerns methods of performing *ex vivo* expansion of
gene-modified hematopoietic stem cells which are useful for many applications
involving bone marrow transplantation and *ex vivo* gene therapy. The present
invention also includes the gene-modified hematopoietic stem cells.

BACKGROUND OF THE INVENTION

15   Hematopoietic stem cells represent attractive targets for genetic modification since
their progeny make up the entire spectrum of the hematopoietic system. Gene therapy
involving stem cells is thus an expanding field that potentially has important
applications in the treatment of a wide range of diseases [Nienhuis, AW, *et al.,*
Cancer, **67**:2700 (1991)]. However, due to the inherent quiescent nature of stem

20   cells, retroviral gene transfer is limited since stable integration requires cell division.
Improved transduction of this target cell population is thus one of the major goals of
current gene therapy research. In the mouse, gene transfer and repopulation with
genetically-modified bone marrow stem cells following transplantation has been
reported [Lemischka, IR, *et al.,* *Cell*, **45**:917 (1986) and Dick, *et al.,* *Cell*, **42**:71

25   (1985)]. Whereas the level of stem cell gene transfer and expression are relatively
modest, it has been sufficient to investigate effects of gene expression on
hematopoiesis [Persons, *et al.,* *Blood* **90:1777** (1997)]. In humans, only an extremely

2

low number of transgenic stem cells persist on a long-term basis [Brenner, *et al.*, *Lancet*, 342:1134 (1993) and Brenner, *et al.*, *Lancet*, 341:85 (1993)] and Rill, *et al.*, *Blood*, 84:380 (1994)]. Therefore there is a need for increasing the proportion of such transduced stem cells through *ex vivo* expansion following transduction and/or

5 through *in vivo* selection approaches.

Most current protocols for transduction of stem cells employ *in vitro* liquid suspension culture with hematopoietic growth factors. It is now well established that culturing murine bone marrow cells for 4 days in the presence of defined concentrations of interleukin-3, interleukin-6, and stem cell factor does not adversely

10 effect overall stem cell survival and function. However, expansion beyond this point has not proven to be beneficial and results in depletion of the reconstitution potential of the bone marrow graft. Cytokine-stimulated stem cells cultured in expansion conditions typically either undergo differentiation or programmed cell death (apoptosis). More mature populations such as the CFU-S and CFU-C, however, are

15 capable of significant expansion in culture. However, these cells are distinct from stem cells and only provide short to moderate-term repopulating ability in transplanted mice. In humans, the long-term culture-initiating cell (LTC-IC) can be expanded *in vitro* with appropriate combinations and amounts of growth factors. LTC-ICs have recently been shown to be more mature than the SCID mouse

20 repopulating cell (SRC) [Dick *et al.*, *Cell* 42:71 (1985)]. SRCs are depleted in cultures that are more than 4 days old, which is consistent with the SRC being a more primitive cell type. More recently, culturing hematopoietic stem cells derived from the AGM (a pre-liver intraembryonic site) has been reported [Dzierzak *et al.* WO 98/12304, hereby incorporated by reference in its entirety]. However, the prior art

25 teaches at most a four-fold expansion of human hematopoietic cells [Bhatia *et al.*, J. Exp. Med., 186:619-624 (1997)].

Methodology for enriching pluripotent stem cells in culture could have a major impact on treatment of blood and immune-system disorders. For example, bone marrow transplantation is often the only option for persons having hematopoietic and immune-

system dysfunctions caused by congenital disorders and/or chemotherapy or radiation

therapy. In addition, enriching pluripotent stem cells should greatly enhance the

treatment of immunodeficency disorders. Furthermore, the effectiveness of the

treatment of blood diseases by *ex vivo* gene therapy, *e.g.*, treating sickle cell anemia or

5   thalassemia, could also be substantially enhanced.   Therefore, expansion of primitive

stem cells in culture would be a major advance for all aspects of bone marrow

transplantation as well as gene therapy applications. Unfortunately, despite the clear

need for such methodology, heretofore, it has not been realized.

The citation of any reference herein should not be deemed as an admission that such

10   reference is available as prior art to the instant invention.

SUMMARY OF THE INVENTION

One important aspect of the present invention is a method of performing *ex vivo*

expansion of a gene-modified hematopoietic stem cell. One embodiment of this type

comprises transducing a hematopoietic stem cell with a nucleic acid encoding a

15   transmembrane efflux pump and then culturing the transduced cell, *i.e.* the

gene-modified hematopoietic stem cell, *ex vivo*, thereby expanding the gene-modified

hematopoietic stem cell. In a preferred embodiment, the gene-modified hematopoietic

stem cell is expanded at least 10-fold.

As exemplified below in one embodiment the transmembrane efflux pump is human

20   multidrug resistance-1 (*i.e.*, MDR-1, the P-glycoprotein) which is encoded by the

nucleotide sequence of SEQ ID NO:1 and has the amino acid sequence of SEQ ID

NO:2 . In another embodiment the transmembrane efflux pump is murine MDR-1

which is encoded by the nucleotide sequence of SEQ ID NO:5 and has the amino acid

sequence of SEQ ID NO:6 . In yet another embodiment the transmembrane efflux

25   pump is murine MDR-3 which is encoded by the nucleotide sequence of SEQ ID

NO:7 and has an amino acid sequence of SEQ ID NO:8. In a particular embodiment

inhibitors of P-glycoprotein, such as PSC833, are added to the expansion culture. In

4

yet another embodiment the transmembrane efflux pump is MRP (multidrug resistant protein). In still another embodiment, the transmembrane efflux pump is the cystic fibrosis membrane transporter.

In one embodiment, the method comprises culturing the gene-modified hematopoietic
5   cell in the presence of one or more cytokines. In one such embodiment the culture contains 5 to 300 ng/ml of the cytokine. In a particular embodiment the culture contains 10 to 50 ng/ml of the cytokine. In another embodiment the culture contains 0.5 to 10 ng/ml of the cytokine.

In one embodiment the cytokine is an early-acting hematopoietic cytokine. In a
10   particular embodiment the cytokine is interleukin-3. In another embodiment the cytokine is interleukin-6. In still another embodiment the cytokine is stem cell factor. In still another embodiment the cytokine is G-CSF. In yet another embodiment the cytokine is GM-CSF. In still another embodiment the cytokine is the FLT-3 ligand. In yet another embodiment the cytokine is interleukin-1. In still another embodiment
15   more than one of these cytokines are present. In a particular embodiment interleukin-3, interleukin-6, and stem cell factor are all present.

In another embodiment of the method of performing *ex vivo* expansion of a gene-modified hematopoietic stem cell, the cell is expanded for at least 3 days. In alternative embodiment the gene-modified hematopoietic stem cell is expanded for at
20   least 6 days. In a particular embodiment the gene-modified hematopoietic stem cell is expanded for at least 9 days. In a preferred embodiment the gene-modified hematopoietic stem cell is expanded for at least 12 days. In a related embodiment the gene-modified hematopoietic stem cell further comprises a second heterologous gene.

In still another embodiment of the method of performing *ex vivo* expansion of a
25   gene-modified hematopoietic stem cell, the hematopoietic stem cell is a mammalian hematopoietic stem cell. In a particular embodiment the mammalian hematopoietic stem cell is a murine hematopoietic stem cell. In a preferred embodiment the

5

mammalian hematopoietic stem cell is a human hematopoietic stem cell. In another

preferred embodiment the gene-modified hematopoietic stem cell expresses a

splice-corrected version of the human MDR-1, as exemplified below.

In another embodiment the method comprises transducing the hematopoietic stem cell

5   with a viral vector that comprises a nucleic acid encoding a transmembrane efflux

pump. In a particular embodiment the transmembrane efflux pump is MDR-1. In one

such embodiment the viral vector is a herpes simplex viral vector. In another

embodiment the viral vector is an adenoviral vector. In still another embodiment the

viral vector is an adeno-associated viral vector (AAV). In a particular embodiment

10   the viral vector is a defective virus, preferably not encoding a gene for a functional

viral protein.

In an alternative embodiment of the method, the viral vector is a retroviral vector. In

one such embodiment the retroviral vector is an HIV retroviral vector. In another

embodiment the vector is a VL 30 vector. In yet another embodiment the vector is a

15   MSCV retroviral vector. As exemplified below the retroviral vector can be a Harvey

Murine Sarcoma Vector. In one such embodiment the hematopoietic stem cell is

transduced by being co-cultured with a retroviral producer cell line. In still another

embodiment of the method, transducing the hematopoietic stem cell with a

transmembrane efflux pump, e.g., MDR-1, is performed with a DNA vector (i.e., a

20   naked DNA) that comprises a nucleic acid encoding the MDR-1.

In a particular embodiment the nucleic acid encoding a transmembrane efflux pump,

e.g., MDR-1, is introduced into the hematopoietic stem cell with a non-integrating

vector e.g., an adenoviral vector. Such an adenoviral vector would only be expressed

transiently, during the period of in vitro expansion. This contrasts with the retroviral

25   vector exemplified below which is integrated and expressed continuously in vivo. In

another embodiment, the nucleic acid encoding MDR-1 is introduced into the

hematopoietic stem cell with Murine Stem Cell Virus which lacks the VL30

6

sequences in the Harvey Murine Sarcoma vector [Hawky *et al.*, *Gene Therapy* 1:136 (1994)].

The present invention further provides a gene-modified hematopoietic stem cell that has been transduced with a nucleic acid encoding a transmembrane efflux pump, *e.g.*

5   MDR-1 and has been expanded. In one embodiment the hematopoietic stem cell is a mammalian hematopoietic stem cell. In a particular embodiment the hematopoietic stem cell is a murine hematopoietic stem cell. In a preferred embodiment the mammalian hematopoietic stem cell is a human hematopoietic stem cell. In another preferred embodiment the gene-modified hematopoietic stem cell expresses a

10   splice-corrected version of the human MDR-1 as exemplified below.

In one embodiment the gene-modified hematopoietic stem cell has been expanded for at least 3 days. In another embodiment the gene-modified hematopoietic stem cell has been expanded for at least 6 days. In a particular embodiment the gene-modified hematopoietic stem cell has been expanded for at least 9 days. In a preferred

15   embodiment the gene-modified hematopoietic stem cell of has been expanded for at least 12 days. In a particular embodiment of this type the gene-modified hematopoietic stem cell has been expanded for 16 days or more. In a related embodiment the gene-modified hematopoietic stem cell further comprises a second heterologous gene.

20   Methods of engrafting an animal with the gene-modified hematopoietic stem cell of the present invention are also provided. Preferably, the gene-modified hematopoietic stem cell has been expanded as taught herein. One embodiment comprises placing the expanded gene-modified hematopoietic stem cell into an animal. In one such method, placing the cell into the animal is performed by injection. In a particular embodiment

25   more than one injection is made. In another embodiment multiple injections are made over the course of several days (*e.g.*, in humans 1 to 20 days appears to be a reasonable range). In one embodiment the animal is a mammal. In a particular embodiment the mammal is a mouse. In a preferred embodiment the mammal is a

7

human. Preferably the engrafted cell is stable for at least three months, and more preferably six months, or a year or even longer.

The present invention further provides methods of treating an animal in need of treatment for a hematopoietic stem cell deficiency using a method of engrafting of the

5 present invention. In one embodiment of this method the hematopoietic stem cell is transduced ex vivo with a nucleic acid encoding a transmembrane efflux pump, e.g. MDR-1. The transduced hematopoietic stem cell (a gene-modified hematopoietic stem cell) is expanded and then engrafted into the animal. In a preferred embodiment, the hematopoietic stem cell is obtained from the animal in need of treatment, and then

10 after being transduced with a nucleic acid encoding MDR-1 and expanded, the resulting gene-modified hematopoietic stem cell is placed back into the animal. In a particular embodiment the animal is a mammal. In a preferred embodiment of this type, the mammal is a human.

A gene-modified hematopoietic stem cell used in a method of engrafting an animal of

15 the present invention can further comprise a second heterologous gene. Such methods include ex vivo gene therapy which may be used to treat diseases involving a dysfunctional cell that is derived from an hematopoietic stem cell. Thus, any genetic defect that could be corrected by bone marrow transplantation can be treated by the methods described herein. In one such embodiment, the second heterologous gene

20 encodes a functional β-globin. In another embodiment, the second heterologous gene encodes a functional adenosine deaminase. In still another embodiment, the second heterologous gene encodes a functional glucocerebrosidase.

Accordingly, it is a principal object of the present invention to provide a method of expanding hematopoietic stem cells ex vivo.

25 It is a further object of the present invention to provide an expanded hematopoietic stem cell.

8

It is a further object of the present invention to provide a method for reconstituting bone marrow cells in an animal subject after the animal has undergone chemotherapy or radiation therapy.

It is a further object of the present invention to provide a method for providing bone
5   marrow cells for a human subject while the human is undergoing chemotherapy.

It is a further object of the present invention to provide a method of engrafting a gene-modified hematopoietic stem cell into an animal subject.

It is a further object of the present invention to provide a method of performing *ex vivo* gene therapy on an animal subject by engrafting an expanded gene-modified
10   hematopoietic stem cell into the animal subject wherein the gene-modified hematopoietic stem cell further comprises a therapeutic gene.

These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

15   Figures 1A-1B show the expansion kinetics for total cells (Figure 1A) and drug-resistant progenitors (Figure 1B) following retroviral transduction. Cells were maintained in liquid suspension cultures with addition of murine IL-3, human IL-6, and rat SCF. Figure 1A shows a typical cell expansion for cells from either MDR-1 or DHFR co-cultures. No significant difference in cell expansion was noted between
20   these groups. Cells were removed at 6 day intervals and assayed for clonogenic progenitors in methylcellulose. Selective concentrations of taxol or trimetrexate were used to determine MDR-1 or DHFR expressing progenitor cells respectively. Figure 1B shows the drug-resistant progenitor population was found to expand extensively and typically reached 100-fold by 2 weeks.

Figures 2A-2B show the long-term analysis of engraftment with donor bone marrow in non-irradiated recipients. HW80 recipient mice were injected for 5 consecutive days with transduced bone marrow cells (C57) which had been expanded in culture for 12 to 16 days. Later the same day, mice were treated with trimetrexate (130

5   mg/kg) and NBMPR-P (20 mg/kg). Beginning at 1 week post-transplant, donor C57 hemoglobin levels were quantitated by electrophoresis on cellulose acetate gels. Persistent engraftment was only seen in mice receiving expanded bone marrow cells transduced with HaMDR-1 (5/12) as shown in Figure 2B. Engrafted mice included: MDR 7 (■), MDR 11 (▲), MDR 18 (◆), MDR 20 (▼) and from the second

10   experiment MDR 15 (●). No stable engraftment was seen in mock-transduced (0/8) or DHFR-transduced (0/8) expanded bone marrow as shown in Figure 2A. Shown in Figures 2A-2B are mice from 2 independent expansion experiments.

Figures 3A-3C show representative hemoglobin electrophoresis gels from non-irradiated mice engrafted with expanded bone marrow (5 months post-BMT for

15   MDR 20 and 7 months post-BMT for all others). C57 bone marrow was used as the donor marrow for transduction and expansion. Recipient mice were HW80. The differing hemoglobin patterns are indicated in Figure 3A. Primary recipients shown in Figure 3B are MDR 7, 11, 18, 20 from expt. #1 and MDR 15 from expt. #2. Secondary irradiated recipients were transplanted with marrow cells from MDR 20

20   demonstrating persistence of donor engraftment following secondary transplant, (a formal proof of stem cell engraftment) as shown in Figure 3C. Figure 3D shows the FACS analysis for P-glycoprotein (Pgp) expression in red blood cells from engrafted mice. Peripheral red blood cells were stained with a monoclonal antibody to human Pgp followed by FACS analysis for the PE chromophore. As a negative control, a

25   mouse injected with HaDHFR-transduced marrow (DHFR #1) is shown. All 4 mice from expt. #2 analyzed at 10 weeks post-transplant demonstrate significant levels of Pgp positive red blood cells. When corrected for the percent donor red cells present at the time of analysis, levels of Pgp positivity approached 100% of circulating donor red blood cells.

Figures 4A-4C show the competitive repopulation assay to determine the relative stem cell content of *ex vivo* expanded bone marrow versus fresh non-expanded marrow. C57 donor bone marrow cells were transduced with HaMDR-1. HW80 donor bone marrow cells were transduced with HaDHFR. Cells were expanded for 12 days in

5   culture then combined according to hind limb volume. 0.005 vols. expanded cells were competed against 0.25 vols. of fresh competing marrow. MDR-1 expanded cells effectively competed against fresh HW80 marrow (Figure 4A, left). DHFR-expanded marrow was completely out competed by fresh C57 marrow (Figure 4A, middle). When MDR-1 (C57) was competed against DHFR (HW80) at equal vols. mice

10   reconstituted solely with MDR-1 marrow, indicating a much greater stem cell content (Figure 4A, right). The comparison of the bands for the distinctive Hb patterns of C57 and HW80 are shown in Figure 4B. Figure 4C shows the Hb patterns in recipient mice (lanes 1-10) as analyzed by Hb electrophoresis.

Figure 5 shows the secondary CFU-S analysis for HaMDR-1 marked primitive

15   hematopoietic cells. At time points from 10 to 24 weeks post-transplant, primary recipients from MDR vs. DHFR competitive repopulation mice (n=6) and MDR 15 were sacrificed and bone marrow cells were injected into secondary recipients. Day 12 CFU-S were harvested and DNA was prepared for Southern blot analysis. DNA was restricted with EcoR1 and probed with an MDR-1 specific probe. A band of the

20   correct size was seen in all CFU-S examined (88/88) from 7 individual mice. 56 representative examples are shown. Negative controls included CFU-S from mice transplanted with untransduced bone marrow. All 10 of these (4 shown) did not contain HaMDR-1 retroviral DNA.

Figure 6A shows the kinetic analysis of HaMDR-1 transduced stem cell expansion.

25   Bone marrow cells were transduced with the HaMDR-1 retrovirus and expanded for the indicated time points. HaMDR cells (0.02 vols/HW80 background) were combined with fresh competed marrow (0.25 vols/C57 background) and injected into lethally irradiated mice. Unexpanded MDR-1 bone marrow (day 0) did not out compete fresh marrow. However, expansion for 3 to 12 days resulted in a progressive

increase in engraftment. Figure 6B shows Southern blot analysis of hemoglobin DNA
for multilineage engraftment. DNA was prepared from the peripheral blood of mice
#20, 21, and 26. DNA was restricted with EcoR1 and probed with a
hemoglobin-specific probe. The appropriate bands are indicated by an arrow for both

5   C57 (single) and HW80 (diffuse). The level of lympho-myeloid engraftment
determined by DNA analysis correlates very well with the level of engraftment
determined in the erythroid lineage by hemoglobin electrophoresis.

Figure 7A shows the kinetics of white blood cell elevation in mice engrafted with
expanded bone marrow. The WBC count for all 10 engrafted mice from Figures 6A-

10   6B are shown as they were examined serially. Mice typically had a long latent period
of above normal to normal WBC counts followed by a rapid phase observed from 5 to
8 months later. Two mice from this experiment maintain long-term engraftment and
continue to have normal WBC counts at time points 8.5 months post-transplant.
Figure 7B shows Wright-stained peripheral blood smears from mice displaying an

15   abnormal cell population. A normal mouse smear at the indicated magnifications is
shown (top). The second example demonstrates the most common morphology seen
(middle). In a few rare cases, the third blast-like phenotype was seen indicating
probable transformation from a myeloproliferative disorder into a leukemia (bottom).

DETAILED DESCRIPTION OF THE INVENTION

20   The present invention provides methods of performing *ex vivo* expansion of
gene-modified hematopoietic stem cells which are useful for many applications
including bone marrow transplantation, and *ex vivo* gene therapy. In addition, the
present invention provides methods of engrafting the gene-modified hematopoietic
stem cells of the present invention into animals, including for bone marrow

25   transplantation and *ex vivo* gene therapy. Therefore the present invention provides
methods of treating an animal in need of treatment for a hematopoietic stem cell
deficiency using a method of engrafting the expanded gene modified hematopoietic
stem cells of the present invention. In one such embodiment the hematopoietic stem

cell is transduced *ex vivo* with a nucleic acid encoding a transmembrane efflux pump, *e.g.* MDR-1. The transduced hematopoietic stem cell (*i.e.*, a gene-modified hematopoietic stem cell) is expanded and then engrafted into the animal. Preferably the hematopoietic stem cell used is matched with the recipient animal to minimize

5   and/or prevent host rejection. Thus, the hematopoietic stem cell is preferably obtained from the animal in need of treatment, and then after being transduced with a nucleic acid encoding MDR-1 and expanded, the resulting gene-modified hematopoietic stem cell is placed back into the animal. The treatments as described herein may be used for any hematopoietic stem cell deficiency including that due to radiation therapy

10   and/or chemotherapy, *e.g.*, as used in cancer treatments. One particular advantage for treating a hematopoietic stem cell deficiency due to chemotherapy with a method of the present invention is that a gene-modified hematopoietic stem cell transduced with a nucleic acid encoding MDR-1 will also be protected from the chemotherapeutic and its adverse effects. Therefore, the engrafting of the gene-modified hematopoietic stem

15   cell into the recipient animal can be performed concomitantly with the chemotherapy.

The *ex vivo* gene therapy methodology of the present invention can be used for treating any disorder (particularly a genetic disorder) that involves a defect in a cell derived from a hematopoietic stem cell including but not limited to the treatment of thalassemia (*e.g.*, with an expanded modified hematopoietic stem cell encoding

20   human β-globin), Gaucher's disease (*e.g.*, with an expanded modified hematopoietic stem cell encoding glucocerebrosidase), sickle cell anemia, and leukemia.

The present invention further provides the expanded gene-modified hematopoietic stem cells used and/or produced by such methods. Such expanded gene-modified hematopoietic stem cells can also contain a second heterologous gene.

25   In addition, the ability of expanding the otherwise rare hematopoietic stem cells provided by the present invention provides a source of hematopoietic stem cells which is large enough in quantity to allow standard biochemical analysis to be performed on this relatively unstudied cell type. Indeed, the present invention results

in the capability of the expanding of human hematopoietic stem cells that is greatly
increased from the maximum of about four-fold expansion taught in the prior art.
Thus, the present invention provides a means for performing facile assays for
identifying factors involved in the regulation of the proliferation *versus* differentiation

5   of hematopoietic stem cells, particularly human hematopoietic stem cells. Such
assays, for example, can be based on the experimental conditions taught herein and
the administration of fractionated cellular extracts. Naturally occurring factors can be
identified by such assays and then isolated by convention biochemical procedures.
Alternatively, chemical libraries and/or phage libraries can be used in an analogous

10   drug screening assays. These naturally occurring factors and drugs can then be used
to manipulate the fate of hematopoietic stem cells initially *in vitro* and eventually *in*
vivo. Indeed, currently there are no known factors which specifically lead to the
proliferation of hematopoietic stem cells in the absence of differentiation.

In Example 1, below, bone marrow cells were transduced with a Harvey (Ha)/MDR-1

15   retrovirus and expanded for 12 days in the presence of interleukin (IL)-3, IL-6, and
stem cell factor (SCF). Long-term engraftment in non-irradiated mice was observed
after transplantation of the cells which were transduced with Ha/MDR-1. To compare
relative repopulating activities of expanded vs. unexpanded cells, competitive
repopulation experiments in irradiated recipients were performed. These results

20   showed at least a 10-fold increase in the absolute number of repopulating cells relative
to fresh untransduced marrow. The results demonstrate that MDR-1 overexpression
allows dramatic cytokine-driven expansion of hematopoietic stem cells *in vitro*.

Therefore, if appearing herein, the following terms shall have the definitions set out
below.

25   A "hematopoietic stem cell" is a pluripotent cell that is able to either replicate itself
with self-renewal divisions or to differentiate along a number of pathways and thereby
generate erythrocytes, granulocytes, monocytes, mast cells, lymphocytes, and

14

megakaryocytes. These stem cells occur with a frequency of about 1 stem cell per 10^4 bone marrow cells.

A "heterologous gene" as used herein is a gene that is introduced into a hematopoietic stem cell through a molecular biological manipulation. As defined herein, this

5 molecular biological manipulation is made such that the heterologous gene is inserted into the hematopoietic stem cell. The heterologous gene need not be expressed in the stem cell as long as it is expressed in the progeny of the stem cell. The coding sequence of the heterologous gene is operatively linked to an expression control sequence. Generally a heterologous gene is first placed into a vector. The

10 heterologous gene is not necessarily naturally contained by the vector, though a heterologous gene can encode a protein that is native to a hematopoietic stem cell. For example, the heterologous gene can encode a functional protein and be used in *ex vivo* gene therapy to replace the corresponding defective gene in an hematopoietic stem cell. The heterologous gene will usually be flanked by DNA that does not flank

15 the genomic DNA in the genome of the source organism. Alternatively, the heterologous gene may not be naturally found in the hematopoietic stem cell such as the gene for human MDR-1 introduced into a murine hematopoietic stem cell.

A cell has been "transduced" by a heterologous gene such as the MDR-1 gene (*i.e.*, a nucleic acid encoding MDR-1), when the gene has been introduced inside the cell and

20 the coding sequence of the gene is operatively linked to an expression control sequence. The transducing gene is carried by a vector and the gene may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. A stably transduced cell is one in which the transducing gene has become integrated into a chromosome so that it is inherited by daughter cells through

25 chromosome replication. This stability is demonstrated by the ability of the cell to establish cell lines or clones comprised of a population of daughter cells containing the transducing gene. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

As used herein a "gene-modified hematopoietic stem cell" is a hematopoietic stem cell that has been transduced by a heterologous gene. A gene-modified hematopoietic stem cell transduced with a nucleic acid encoding MDR-1 (the MDR-1 gene) is exemplified below.

5   As used herein the "expansion" of an hematopoietic stem cell indicates that there is an increase in the absolute number of hematopoietic stem cells, i.e., during the culturing of the cells. Analogously, an hematopoietic cell that has undergone such expansion has been "expanded".

As used herein "engrafting" a hematopoietic stem cell, preferably an expanded
10   hematopoietic stem cell, means placing the hematopoietic stem cell into an animal, e.g., by injection, wherein the stem cell persists in vivo. This can be readily measured by the ability of the hematopoietic stem cell to contribute to the ongoing blood formation.

A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions
15   as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. The term "vector" can also refer to a recombinant virus or defective virus containing a
20   replicon to which another DNA segment may be attached.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-
25   stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-

16

stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

5   A "coding sequence" is a nucleic acid sequence which can be reverse transcribed (*i.e.*, when part of a retroviral vector) and/or transcribed and then translated into a polypeptide *in vitro* and/or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl)

10   terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

15   A nucleic acid sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and/or translation of that nucleic acid sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the nucleic acid sequence to be expressed and maintaining the correct reading frame to permit expression of the

20   nucleic acid sequence under the control of the expression control sequence and production of the desired product encoded by the nucleic acid sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal for example, such a start signal can be inserted in front of the gene.

25   Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5'

5   direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but

10   not always, contain "TATA" boxes and "CAT" boxes.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

Any of a wide variety of expression control sequences -- sequences that control the

15   expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma, adenovirus, herpes virus and other sequences known to control the expression of genes of mammalian cells, and various combinations thereof.

20   In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Considering these and other factors a person skilled in the art will be able to construct a variety of

25   vector/expression control sequence combinations that will express the heterologous genes used in the present invention.

A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves

5   the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes. For instance, alpha-factor, a native yeast protein, is secreted from yeast, and its signal sequence can be attached to heterologous proteins to be secreted into the media (See U.S. Patent 4,546,082, EPO 0 116 201, publication date 12 January 1983; U.S. Patent Application Serial No. 522,909, filed 12 August

10   1983). Further, the alpha-factor leader and its analogs have been found to secrete heterologous proteins from a variety of yeast, such as Saccharomyces and Kluyveromyces, (EPO 88312306.9 filed 23 December 1988; U.S. Patent Application Serial No. 139,682, filed 30 December 1987, and EPO Publication No. 0 301 669, publication date 1 February 1989).

15   The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state

20   government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as

25   peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent,

more preferably by at least 90 percent, and most preferably prevent, a clinically
significant deficit in the activity, function and response of the host. Alternatively, a
therapeutically effective amount is sufficient to cause an improvement in a clinically
significant condition in the host.

5   Vectors

According to the present invention, the vector for *ex vivo* administration of the gene
encoding MDR-1 (*i.e.*, a nucleic acid encoding MDR-1) and/or an alternative
heterologous gene can be introduced via any strategy. Vectors can be introduced to
transduce the desired host cells *ex vivo* by methods known in the art, *e.g.*, transfection,
10 electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate
precipitation, lipofection (lysosome fusion), use of a gene gun, using a viral vector,
with a DNA vector transporter, and the like. Alternatively, the vector can be
introduced by lipofection.

Viral vectors are commonly used for *ex vivo* targeting and therapy procedures; these
15 include DNA-based vectors and retroviral vectors. Methods for constructing and
using viral vectors are known in the art [*see, e.g.*, Miller and Rosman, *BioTechniques*
7:980-990 (1992)]. DNA viral vectors include an attenuated or defective DNA virus,
such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr
virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective
20 viruses, which entirely or almost entirely lack viral genes, are preferred. Defective
virus is not infective after introduction into a cell. In addition, different viral vectors
may exhibit specificity for one or another cell type. Examples of particular vectors
include, but are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et al.,
Molec. Cell. Neurosci. 2:320-330 (1991)], defective herpes virus vector lacking a
25 glyco-protein L gene [Patent Publication RD 371005 a], or other defective herpes
virus vectors [International Patent Publication No. WO 94/21807, published
September 29, 1994; International Patent Publication No. WO 92/05263, published
April 2, 1994]; an attenuated adenovirus vector, such as the vector described by

20

Stratford-Perricaudet et al. [*J. Clin. Invest.* 90:626-630 (1992); *see also* La Salle et al.,

Science 259:988-990 (1993)]; and a defective adeno-associated virus vector [Samulski

et al., *J. Virol.* 61:3096-3101 (1987); Samulski et al., *J. Virol.* 63:3822-3828 (1989);

Lebkowski et al., *Mol. Cell. Biol.* 8:3988-3996 (1988)]. Herpes virus vectors are

5   preferred for dendritic cells.

In another embodiment, the gene can be introduced in a retroviral vector, *e.g.*, as

described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell

33:153; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No.

4,980,289; Markowitz et al., 1988, J. Virol. 62:1120; Temin et al., U.S. Patent No.

10   5,124,263; International Patent Publication No. WO 95/07358, published March 16,

1995, by Dougherty et al.; and Kuo et al., 1993, Blood 82:845. International Patent

Publication No. WO 95/07358 describes high efficiency transduction of primary B

lymphocytes. In a specific embodiment, exemplified below, a Harvey murine

retroviral vector is used to transduce hematopoietic stem cells. Retroviral vectors can

15   be constructed to function as infectious particles or to undergo a single round of

transfection. In the former case, the virus is modified to retain only those genes

responsible for packaging and replication and to express the heterologous gene. Non-

infectious viral vectors are prepared to destroy the viral packaging signal, but retain

the structural genes required to package the co-introduced virus engineered to contain

20   the heterologous gene and the packaging signals. Thus, the viral particles that are

produced are not capable of producing additional virus.

For the past decade, there has been increasing use of liposomes for encapsulation and

transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the

difficulties and dangers encountered with liposome mediated transfection can be used

25   to prepare liposomes for *in vivo* or *ex vivo* transfection of a gene encoding a marker

[Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* 84:7413-7417 (1987); *see* Mackey, et

al., *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031 (1988); Ulmer et al., *Science*

259:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of

negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* 337:387-388 (1989)].

It is also possible to introduce the vector as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods

5 known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [*see, e.g.*, Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams et al., *Proc. Natl. Acad.*

10 *Sci. USA* 88:2726-2730 (1991)].

The present invention includes vectors containing a gene (i.e., nucleic acid) encoding a transmembrane efflux pump, *e.g.*, MDR-1. Also included are truncated forms, analogs and derivatives of the transmembrane efflux pump, *e.g.*, MDR-1 that have essentially the same or improved functional activity as MDR-1, for example.

15 Therefore, the production and use of derivatives and analogs related to MDR-1, for example are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with a full-length, wild-type MDR-1 protein.

In particular, MDR-1 derivatives, for example, can be made by altering encoding

20 nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity as it relates to the present invention, relative to the native MDR-1, for example.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which

25 encode substantially the same amino acid sequence as a MDR-1 gene, for example, may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of MDR-1 genes which are altered

22

by the substitution of different codons that encode the same amino acid residue within

the sequence, thus producing a silent change. Likewise, the MDR-1 derivatives of the

invention include, but are not limited to, those containing, as a primary amino acid

sequence, all or part of the amino acid sequence of a MDR-1 protein including altered

5   sequences in which functionally equivalent amino acid residues are substituted for

residues within the sequence resulting in a conservative amino acid substitution. For

example, one or more amino acid residues within the sequence can be substituted by

another amino acid of a similar polarity, which acts as a functional equivalent,

resulting in a silent alteration. Substitutes for an amino acid within the sequence may

10   be selected from other members of the class to which the amino acid belongs. For

example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine,

valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino

acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.

The positively charged (basic) amino acids include arginine, lysine and histidine. The

15   negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Additionally, the nucleic acid sequence encoding a transmembrane efflux pump, such

as MDR-1, can be mutated *in vitro* or *in vivo*, to create and/or destroy translation,

initiation, and/or termination sequences, or to create variations in coding regions

and/or form new restriction endonuclease sites or destroy preexisting ones, to

20   facilitate further *in vitro* modification. Preferably, such mutations enhance the

functional activity of the mutated MDR-1 gene product, for example. Any technique

for mutagenesis known in the art can be used, including but not limited to, *in vitro*

site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem. 253:6551;

Zoller and Smith, 1984, DNA 3:479-488; Oliphant et al., 1986, Gene 44:177;

25   Hutchinson et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:710), use of TAB® linkers

(Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see

Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and

Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-

70).

30

Expression vectors containing a transmembrane efflux pump gene, such as the MDR-1 gene, inserts can be identified by many ways including : (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of "marker" gene functions, and (d) expression of inserted

5   sequences. In the first approach, the nucleic acids can be amplified by PCR with incorporation of radionucleotides or stained with ethidium bromide to provide for detection of the amplified product. In the second approach, the presence of a MDR-1 gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted MDR-1 gene.

10 In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (*e.g.*, β-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In the fourth approach, recombinant

15 expression vectors can be identified by assaying for the activity of the MDR-1 gene product expressed by the recombinant.

                              Promoters

According to the present invention, the gene encoding MDR-1 and/or a second heterologous gene can be under the control of any promoter. In a specific

20 embodiment, the human cytomegalovirus (CMV) immediate early promoter is used to effect transient expression of MDR-1. Alternatively, an inducible promoter can be used. However, the present invention contemplates use of any promoter to control expression of MDR-1. Selection of the promoter depends on the desired use. For example, expression of MDR-1 may be controlled by any promoter/enhancer element

25 known in the art, but these regulatory elements must be functional in the host or host cell selected for expression. Promoters which may be used to control MDR-1 gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the

herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A.
78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al.,
1982, Nature 296:39-42); and using a transcriptional control region such as the beta-
globin gene control region which is active in myeloid cells (Mogram et al., 1985,

5   Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94). Alternatively, expression of
the MDR-1 gene can be under control of an inducible promoter, such as
metallothionein promoter, which is induced by exposure to heavy metals.

<u>Bone marrow transduction</u>

Bone marrow cells can be obtained from any number of sources from an animal,
10   including a human subject. For example, the cells can be harvested from iliac bone
marrow. Alternatively, hematopoietic stem cells can be obtained from umbilical
chord cells. Another source for hematopoietic stem cells is from circulating fetal
blood cells. In addition, a human subject, for example, can be treated with a cytotoxic
drug and/or a hematopoietic stem cell stimulating cytokine (*e.g.*, G-CSF).

15   Mononuclear cells can then be collected by leukophoresis and the hematopoietic stem
cells can be isolated from the peripheral blood cells by their selective binding to an
antibody raised against CD34.

In the example below, bone marrow cells were flushed from the hind limbs of a
laboratory animal and prestimulated for 48 hours in an appropriate medium.
20   Dulbecco's modified essential medium supplemented with 15% fetal bovine serum,
100 units/ml penicillin, and 100 ng/ml streptomycin (P/S; Gibco-BRL) was also used
in the Example below. Growth factors can also be included in the suspension culture
at the appropriate concentration. Following prestimulation cells can be co-cultured on
irradiated retroviral producer cell lines (e.g., ecotropic producer cell lines for mice and
25   amphotropic producer cell lines for humans) for 48 hours in the presence of the same
growth factor combination but also with added 6 mg/ml polybrene (Sigma) to enhance
transduction.

Ex vivo culture and expansion of myeloid progenitors

After transduction, cells can be cultured. In the Example below, culturing was
performed in the presence of interleukin-3, interleukin-6, and stem cell factor. Any
other cytokine which supports the proliferation of hematopoietic stem cells could be

5   used, including but not limited to GM-CSF, G-CSF and FLT-3 ligand. It is preferred
that when the hematopoietic stem cell is a human cell and/or the recipient is a human
subject that the cytokines used also be the human homolog.

Cells are typically resuspended at 1×10^6 cells/ml every 3-6 days for at least 12 days
of expansion. Aliquots of cells can be removed for CFU-C analysis at various time

10   points. The percentage of drug-resistant progenitors can calculated by plating cells in
methylcellulose (Stem Cell Technologies) for example, in the presence of selective
concentrations of drugs. The percentage of transduced cells are generally found to
remain constant throughout expansion.

Non-irradiated recipient bone marrow transplants

15   For bone marrow transplants into non-irradiated recipients, mice can receive from 1 to
10 daily intravenous injections with a vector containing a nucleic acid encoding
MDR-1, *e.g.*, a total of $20 - 40 \times 10^6$ cells for the 5 day period exemplified below.
(Humans can receive from 1 to 20 such daily intravenous injections, preferably 5 to 10
daily intravenous injections). Following a five day treatment course in Example 1

20   below, the presence of a donor marker protein, Hb as exemplified below, can be
monitored in recipient animal (as exemplified below the monitoring began at one
week after the last injection), and then followed for as long as appropriate, (8 to 14
months in Example 1).

The present invention may be better understood by reference to the following non-

25   limiting Example, which is provided as exemplary of the invention. This example is
presented in order to more fully illustrate the preferred embodiments of the invention.

26

It should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLE 1

EX VIVO EXPANSION OF MURINE HEMATOPOIETIC STEM CELLS

5   TRANSDUCED WITH AN MDR-1 RETROVIRAL VECTOR

Introduction

Initial studies were intended to determine whether gene-modified progenitors could be expanded in culture and whether these relatively mature transduced cells would be useful for chemoprotection against myelosuppression in mice receiving antifolate

10   chemotherapy. This progenitor approach previously has been shown effective with vectors expressing methyguanine DNA methyltransferase [MGMT] and protective against 1,3-bis(2-chloroethly)-1-nitrosourea [BCNU] mediated delayed myelosuppression. Unexpectedly, mice receiving bone marrow transduced with an MDR-1 retrovirus showed sustained engraftment in non-irradiated recipients. In

15   addition, subsequent quantitation of the stem cell content by competitive repopulation experiments in lethally-irradiated mice indicated a large increase in the repopulation potential with expanded MDR-1 marrow. Such results were surprising since there had been numerous observations of negative effects of the expansion of stem cells when alternative gene-modified progenitors had been generated. A myeloproliferative

20   disorder did result in some cases, since a fraction of mice engrafted with MDR-1 marrow developed a myeloproliferative disorder characterized by high peripheral white blood cell counts and splenomegaly. This disorder, however, was not found to be absolutely linked to the stem cell expansion described herein.

Methods

25   *Retroviral producer cell lines and vector constructs*: The Harvey (Ha)MDR-1 and HaDHFRL22Y vectors and ecotropic producer cell lines were generated as described previously [Sorrentino *et al.*, Science **257**: 99-103 (1992); Galipeau *et al.*, *Human*

Gene Therapy 8:1771-1783 (1997), hereby incorporated by reference in their
entireties]. The MDR-1 protein (encoded by SEQ ID NO:1 and having the amino acid
sequence of SEQ ID NO:2) contains a wild-type glycine 185 amino acid. Wild-type
MDR-1 shows increased resistance to etoposide and decreased resistance to vinca

5   alkaloids when compared with the valine 185 mutant (encoded by SEQ ID NO:3 and
having the amino acid sequence of SEQ ID NO:4). The MDR-1 cDNA has been
previously splice-corrected to allow for optimal levels of active protein expression in
transduced cells [Galipeau *et al.*, *Human Gene Therapy* 8:1771-1783 (1997)]. The
DHFRL22Y protein contains a leucine to tyrosine mutation at codon 22 (L22Y) which

10   greatly optimizes resistance to trimetrexate [Spencer *et al.*, *Blood* 87:2579-2587
(1996)].

Retroviral-mediated bone marrow transduction: Bone marrow cells were flushed
from the hind limbs of either C57/Bl6 (C57) or B6.C-H1/BY (HW80) congenic
mouse strains (day -4) and prestimulated for 48 hours in Dulbecco's modified

15   essential medium (DMEM; BioWhittaker, Walkersville, MD) supplemented with
15% fetal bovine serum, 100 units/ml penicillin, and 100 ng/ml streptomycin (P/S;
Gibco-BRL). Growth factors were also included in the suspension culture at the
following concentrations; 20 ng/ml murine IL-3 (Amgen), 50 ng/ml human IL-6
(Amgen), and 50 ng/ml murine SCF (Amgen and R & D Systems) as previously

20   described. Following prestimulation (day -2), cells were co-cultured on irradiated
(1500 rads) GP+E86 ecotropic producer cell lines for 48 hours in the presence of the
same growth factor combination but also with added 6 mg/ml polybrene (Sigma) to
enhance transduction. C57/Bl6 donor mice have a single hemoglobin (Hb) pattern
while HW80 have a diffuse Hb pattern when separated on cellulose acetate gels

25   (Helena Laboratories, Beaumont, Texas). These Hb patterns were subsequently
utilized for characterization of engraftment.

Ex vivo culture and expansion of myeloid progenitors: Following transduction (day
0), cells were cultured in the presence of the growth factor combination described
above. Cells were resuspended at 1 x 10^6 cells/ml every 3-6 days for at least 12 days

28

of expansion. Aliquots of cells were removed for CFU-C analysis at various time

points. The percentage of drug-resistant progenitors was calculated by plating cells in

methylcellulose (Stem Cell Technologies) in the presence of selective concentrations

of drugs. MDR-transduced progenitors were resistant to 50 ng/ml taxol and

5   DHFR-transduced progenitors were resistant to 25 to 50 nM trimetrexate. These

concentrations of trimetrexate completely killed non-transduced background cells

when plated in thymidine phosphorylase-treated methylcellulose. The percentage of

transduced cells was found to remain constant through expansion. Average progenitor

transduction efficiencies were: MDR-1 TaxolR (40.3 + 10.2%), DHFR TrimetrexateR

10   (39.6 + 17.8%).

Non-irradiated recipient bone marrow transplants: During bone marrow transplant

into non-irradiated recipients, mice received 5 daily intravenous injections with either

MDR- or DHFR-transduced bone marrow cells (total of 20 - 40 x 10^6 cells for the 5

day period). Later each day mice also received intraperitoneal injection with

15   trimetrexate (130 mg/kg) and the nucleoside transport inhibitor

nitrobenzylmercaptopurine riboside phosphate (NBMPR-P; 20 mg/kg). Following

this five day treatment course, the presence of donor Hb was monitored in recipient

mice beginning at one week and followed for 8 to 14 months.

Trimetrexate-glucuronate was received as the base from the Drug Synthesis and

20   Chemistry Branch, Developmental Therapeutics Program, Division of Cancer

Treatment, NCI. It was converted to the glucuronate form as described previously

[Spencer et al., Blood 87:2579-2587 (1996)].

Competitive repopulation assays: Expanded MDR-1 transduced cells were mixed

either with the indicated donor hind limbs volume of 12 day expanded DHFRL22Y

25   transduced cells or with freshly harvested marrow. Cells were mixed thoroughly and

injected via the tail-vein into lethally-irradiated (925 - 1000 rads) recipient mice.

Beginning at 10 weeks post-transplant, Hb patterns were analyzed by electrophoresis

on cellulose acetate gels to calculate the relative proportions of single and diffuse

donor hemoglobin in reconstituted mice. The results of these analyses were
quantitated by densitometry.

Secondary bone marrow transplants: Bone marrow was harvested from primary
recipients from 10 to 24 weeks following transplant and injected into

5   lethally-irradiated secondary recipients. Secondary transplanted mice received at least
5 x 10^6 bone marrow cells. Hb patterns were monitored in secondary recipients after
reconstitution (8 to 10 weeks). Secondary CFU-S were harvested 12 days following
injection of 1 - 5 x 10^4 cells and DNA was prepared for Southern blot analysis for the
presence of the MDR-1 transgene.

10   *Southern blot analysis:* DNA was prepared as previously described [Sorrentino *et al.*,
Science **257**: 99-103 (1992)]. Typically 10 to 20 mg of genomic DNA was restriction
digested with either EcoR1 or NheI, and separated on a 1% agarose gel. Gels were
blotted overnight onto Hybond N+ nylon membrane (Amersham), UV crosslinked,
and hybridized with either MDR-1 or hemoglobin-specific [32P]-labeled probes.

15   Blots were washed extensively at 65°C, exposed overnight, and analyzed on a
phosphorimager (Molecular Dynamics).

Detection of human p-glycoprotein on mouse erythrocytes: One microliter of murine
whole blood containing approximately 6 x 10^6 erythrocytes was washed in PBS and
resuspended in 0.5 ml of Fc-Block (Pharmingen, San Diego, CA) in a final volume of

20   20 ml of PBS. The red cells were washed and resuspended in PBS with 0.3 mg of
unlabeled primary anti-human Pgp monoclonal murine antibody 4E3 (M3523, Dako
Corporation, Carpinteria, CA). Cells were next incubated with primary antibody for
45 minutes at room temperature. Cells were then washed and incubated with a
phycoerythrin-linked goat anti-mouse IgG antibody (Caltag Laboratories, Burinlgame,

25   CA) for 30 minutes at room temperature. Cells were next washed and analyzed by
flow cytometry. Red cells and platelets were identified by the characteristic forward
and side scatter distribution. Red cells were gated and analyzed for PE. Leukocytes

30

are located within the erythrocyte gate but these constitute less than 0.1% of all events.

Detection of human p-glycoprotein on mouse leukocytes: Murine whole blood was collected in heparinized tubes and diluted in PBS. Red blood cells were lysed in
5   Gey's solution for 5 minutes on ice. White blood cells were blocked for 15 minutes in PBS/0.1% BSA/10% normal mouse serum followed by staining with a FITC-labeled murine monoclonal anti-human p-glycoprotein antibody (4E3-FITC; Signet Laboratories Inc., Dedham, MA) or with the isotype control. Cells were then analyzed by flow cytometry for FITC-positivity. Gates were drawn on the abnormal population
10 apparent on forward and side scatter profiles in mice with a myeloproliferative disorder.

Assays for replication-competent retrovirus: Genomic DNA was prepared from either cultured producer cell lines, transduced 3T3 cells, or peripheral white blood cells. PCR was performed using primers specific for the 3' end of pol and the 5' end of env
15 regions of the helper virus genome which have been previously described [Scarpa, *Virology* **180**:849 (1991)]. PCR was performed under the following conditions: 94°C, 1.5 minutes denaturation; 55°C, 1.0 minute annealing; 72°C, 1.5 minutes extension; 28 cycles. In addition, marker rescue assays were performed on supernatant from producer cell lines and plasma samples from transplanted mice. A
20 M.dunni/G1Na-transduced cell line was used as the target for marker rescue. Following addition of supernatant, M. dunni/G1Na cells were cultured for at least 2 weeks and supernatant from these cells was assayed at intervals for liberation of infectious retrovirus containing the neo gene. Supernatant were transferred to naive M.dunni cells for 48 hours followed by selection in 0.8 mg/ml G418 (active). No
25 G418R colonies were obtained in multiple experiments at a concentration in which M. dunni/G1Na cells were highly resistant.

Stem cell expansion calculation: 0.005/0.25 + 0.005 = 0.02 predicted engraftment percentage if no stem cell expansion had occurred. Observed engraftment levels =

31

0.25 to 1.0 indicate an increase in stem cell content of at least 10-fold. It should be noted that engraftment levels were constantly increasing thus any single measurement likely underestimates the true stem cell expansion.

Results

5   *Ex vivo* expansion of retrovirally-transduced murine myeloid progenitors was performed as follows. Bone marrow cells were harvested from either C57/Bl6 (C57) or B6.C-H1/BY (HW80) mice (day -4) and transduced by co-culture on retroviral producer cell lines. Producer cells included an MDR-1sc producer which expresses the splice-corrected version of the human MDR-1 cDNA and a resistance-conferring

10   dihydrofolate reductase (DHFR) mutant referred to as DHFRL22Y. Following transduction (day 0), cells placed into liquid suspension culture for a period of 12 days expanded logarithmically (Fig. 1A). At three day intervals, an aliquot of cells was removed and plated in methylcellulose for assay of the progenitor content. Total progenitor and drug-resistant progenitor levels were calculated and monitored over

15   time. The percentage of progenitors within the total cell population peaked at levels close to 20% between 3 and 6 days following initiation of culture and then gradually declined with time. This transient relative enrichment in progenitors is likely due to death of differentiated cells and expansion of the progenitor pool. The absolute numbers of both drug-resistant and drug-sensitive progenitor populations expanded

20   equally during culture. Thus, the relative percentage of drug-resistant progenitors remained constant throughout the 12 days in culture. Examples of representive expansions are shown for both MDR-1 and DHFR-transduced drug-resistant progenitors (Fig. 1B). Typical expansions yielded a 100-fold increase by 2 weeks.

Long-term engraftment of MDR-transduced hematopoietic stem cells was observed in

25   non-irradiated recipient mice. The expansion of cells capable of long-term engraftment in a non-irradiated mouse model was unexpected. MDR- or DHFR-transduced and expanded cells were initially injected into mice with the purpose of testing whether short-term engraftment of drug-resistant progenitors would be

protective against antifolate-induced myelosuppression. Recipient mice were treated for 5 days with trimetrexate in combination with the nucleoside transport inhibitor nitrobenzylmercaptopurine riboside phosphate (NBMPR-P). Mice were injected with 12-16 day-expanded cells on each of the 5 days of drug treatment. Following

5   transplant the donor hemoglobin (Hb) levels were monitored in the recipient mice beginning at 1 week and continued through greater than 1 year following injection (Fig. 2A-2B). Donor Hb was present in varying levels in all mice receiving cells as early as 1 week following injection (the earliest time point examined). However, this engraftment was only transient in mice receiving DHFR- or mock-transduced marrow

10   (0/16; from 2 separate expansion experiments, Fig.2A). By contrast, 5/12 mice which received MDR-transduced marrow showed long-term engraftment which was stable for more than 6 months post BMT (Fig. 2B), and up to 14 months in the latest time point obtained. Representative Hb electrophoresis profiles for primary engrafted recipients demonstrated the presence of C57 donor Hb at time points 5 to 7 months

15   following injection (Fig. 3A-3B). In addition, secondary recipients from mouse #20 showed a range from 50 - 100% C57 donor Hb 8 weeks after transplant indicating engraftment of the primitive long-term repopulating cells (Fig. 3C). High level expression of P-glycoprotein was seen in donor red blood cells at greater than 10 weeks following transplant in all 4 mice engrafted from experiment #1 (Fig. 3D). The

20   FACS data shows expression in total red blood cells and when corrected for donor chimerism at the same day of analysis the levels were found to range from 80 - 100% positivity. DHFR mouse #1 served as a negative control for P-glycoprotein expression.

Expansion of the MDR-transduced hematopoietic stem cells was quantified by

25   competitive repopulation assay. Thus, to examine whether stem cell expansion was responsible for the high levels of engraftment obtained in the non-irradiated model, a competitive repopulation model was used. MDR- and DHFR-transduced cells were expanded over a 12 day period as described in the Methods, above. Table 1 shows the calculation of the percent hind limbs volume remaining at various time points during

30   the expansion. On day 12, MDR-transduced cells were mixed in an equal

33

volume:volume ratio with expanded day 12 DHFR-transduced cells and injected into
lethally-irradiated recipient mice (Figure 4A, right). Also, expanded MDR cells
(0.005 C57 donor volumes, Figure 4A, left) or expanded DHFR cells (0.005 C57
donor volumes Figure 4A, middle) were mixed with freshly isolated cells with the
5   opposing Hb pattern (0.25 donor volumes) and injected into lethally-irradiated
recipients. Beginning at 10 weeks the Hb patterns in recipient mice were analyzed by
Hb electrophoresis (Figure 4C). Interestingly, MDR-expanded marrow completely
out competed identically expanded DHFR marrow in repopulation of recipient mice
indicating a much higher stem cell content, (lanes 4 -10 of Figure 4C). But most
10   surprising was the very high level of engraftment of MDR marrow when competed
against fresh marrow (lanes 1 and 2 of Figure 4C.). By contrast, when DHFR
marrow was competed against fresh marrow it was completely outcompeted (lanes 3
and 4 of Fig. 4C). In addition, over time mice consistently lost their chimerism and
approached 100% donor as was seen in the unirradiated model.

34

TABLE 1

Calculation of Total Cell Expansion and

Percent Hind Limbs Volume Remaining

		HaMDR			HaDHFR		
	Day	Cell Number*	Volume fraction replated	Fraction hind limbs volume	Cell Number*	Volume fraction replated	Fraction hind limbs volume
5	0	2.15×10^7	1.00	0.86	2.06×10^7	1.00	1.00
	3	9.2×10^7	0.22	0.19	6.2×10^7	0.22	0.22
	6	6.6×10^7	0.40	0.076	6×10^7	0.52	0.114
	9	8×10^7	1.00	0.076	7.9×10^7	1.00	0.114
	12	1.6×10^7	---	0.076	8.2×10^7	---	0.114

10   Note: On days 3 and 6 a fraction of the cells were replated while the rest were
discarded. This is reflected in the fraction hind limbs volume remaining.
After 12 days of expansion, 0.005 hind limb volumes were injected per mouse
along with 0.25 for fresh competed marrow. The fraction at day 0 was
determined by the percent of the total volume used following flushing the bone
15   marrow from both fibias and femurs of a single mouse.
* Cell number values are those prior to cell replating

Expanded stem cells are marked with MDR-1 proviral DNA. To determine whether

the engrafted donor cells were transduced with the MDR-1 virus, secondary day 12

CFU-S were analyzed by southern blot (Fig. 5). Genomic DNA from individual

20   CFU-S were digested with EcoR1 and probed with an MDR-1 specific probe. A total

of 88/88 CFU-S from 7 primary recipients (6 MDR vs. DHFR mice from competitive

repopulation expt. #1, and MDR #15 from non-irradiated expt. #2) were shown to be

positive by southern blot for the MDR-1 provirus giving a band of the expected size

(3464 bp). In addition, a subset of samples were digested with NheI which indicated

25   the presence of the correct size full-length retroviral transcript (8580 bp). These data

link the presence of the transgene and expansion of primitive stem cells.

35

The correlation of the stem cell expansion with period of time in culture was next

investigated. To determine the kinetics of stem cell expansion during culture, an

additional competitive repopulation experiment was performed. For this experiment,

the donor and recipient hemoglobins were switched to eliminate any possibility that

.5   engraftment was related to the donor Hb pattern. Following transduction with the

MDR-1 retrovirus, cells were cultured and aliquots competed at a ratio of 0.02 vol.

MDR (HW80)/0.25 vol. fresh (C57) on days 0, 3, 6, and 12. Engraftment of MDR-1

marrow was only seen following at least 3 days of expansion post co-culture and

engraftment increased with increasing time in culture (Figure 6A). In order to

10   determine whether the high levels of engraftment shown in the erythroid lineage by

hemoglobin electrophoresis were also maintained in other lineages, Southern blot

analysis was performed on peripheral blood DNA. Blots were treated with the

restriction enzyme EcoR1 and probed with a hemoglobin allele-specific probe (Figure

6B). The results shown in Figure 6B demonstrate that the levels of donor hemoglobin

15   seen in the peripheral blood and the levels of lympho-myeloid reconstitution

represented in the peripheral blood cell DNA are in full agreement.

In some of the transplanted mice a myeloproliferative disorder was observed.

However, the myeloproliferative disorder is not a necessary consequence of the

engraftment of the expanded gene-modified hematopoietic stem cells transduced with

20   a nucleic acid encoding MDR-1. Engrafted mice were analyzed serially to monitor

the level of engraftment over time. In some mice, it was noticed that the peripheral

white blood cell (WBC) counts began to rise to abnormal levels (Figure 7A). Shown

in Figure 7A are 10 representative engrafted mice from the competitive repopulation

experiment #2, above. 2/10 of these mice retain normal WBC counts at the present

25   time despite a very large stem cell expansion. In most of the cases the elevation was

extremely rapid and could increase by as much as 10-fold within a few days. White

blood cell counts at last analysis ranged from 97,018 to as high as 388,433 cells/ml for

MDR mice compared with normal values of 8654 + 2626 (p<0.001). Analysis of

Wright-stained blood smears (Fig. 7B) showed a relative increase in an abnormal cell

30   population (bottom 2 panels relative to normal mouse in the top panel).

36

Immunophenotyping of the population revealed a high percentage of GR-1 and
MAC-1 positive cells, consistent with the granulocytic morphology of the majority of
these cells. In a few instances, blasts were seen in the peripheral blood consistent
with progression into leukemia. These cells did not stain positively for any lineage

5   marker. The disease was found to be transplantable into secondary recipients which
rapidly developed the same increases in white cell counts.

Replication-competent retrovirus (RCR) assays were also performed extensively on
both cell lines and plasma from mice with the myeloproliferative disorder. A very

10   sensitive PCR assay for helper virus failed to detect the helper genome but was highly
positive when using positive control monkey DNA. In addition, marker rescue assays
on Mus dunni cells eliminated the possibility of contamination with retroviruses of a
wide host range. These data indicate that the stem cell expansion and subsequent
myeloproliferative disorder are not due to a contamination of helper virus.

15   In addition to the elevated WBC count, the number of clonogenic progenitors in the
peripheral blood and spleen increased dramatically. Typical progenitor numbers in
the blood of a normal animal were 1 - 4/105 cells. Progenitor counts in some mice
ranged from 57 to 1290/105 cells. Splenomegaly was also seen in mice with the
myeloproliferative disorder. Spleen weights ranged from 483 to 834 mg compared to

20   106 + 48 mg for normal mice. The progenitor content in the spleen was
concomitantly increased from a normal of 3.3-18/105 to 180/105 cells.

Importantly, despite the abnormal hematologic phenotype, the mice appeared grossly
normal and healthy even with the highest white blood cell counts. Analysis of the
bone marrow revealed no morphological abnormalities consistent with leukemia. In

25   addition, the mouse karyotype was normal and there were no chromosome
translocations present in peripheral blood metaphases from the two representative
mice examined. These data are consistent with a prolonged period of abnormal
myeloproliferation with transformation to leukemia in only a minority of mice.
Peripheral blood cells from several diseased mice were also injected into SCID mice

without the development of tumors. Importantly, a percentage of mice have shown large increases in stem cell content and have maintained normal hematologic parameters for as long as 9 to 14 months following transplant. The myeloproliferative syndrome can be dissociated from the hematopoietic stem cell expansion as shown by

5   a significant number of healthy transplanted mice in which there was no evidence of myeloproliferative syndrome.

The following is a list of documents related to the above disclosure and particularly to the experimental procedures and discussions. These documents, and all others cited above, should be considered as incorporated by reference in their entirety.

10   References

1.   Nienhuis AW, McDonagh KT, Bodine DM: Gene transfer into hematopoietic stem cells. Cancer 67:2700, 1991

2.   Lemischka IR, Raulet DH, Mulligan RC: Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45:917, 1986

15   3.   Dick JE, Magli MC, Huszar D, Phillips RA, Bernstein a: Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42:71, 1985

4.   Szilvassy SJ, Fraser CC, Eaves CJ, Lansdorp PM, Eaves AC, Humphries RK: Retrovirus-mediated gene transfer to purified hemopoietic stem cells with long-term

20   lympho-myelopoietic repopulating ability. Proc.Natl.Acad.Sci.U.S.A. 86:8798, 1989

5.   Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134, 1993

25   6.   Brenner MK, Rill DR, Moen RC, Krance RA, Mirro JJ, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993

7.   Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous

bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994

8.   Dunbar C, Kohn D: Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A

5   phase I study. Hum.Gene Ther. 7:231, 1996

9.   Bodine DM, Karlsson S, Nienhuis AW: Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc.Natl.Acad.Sci.U.S.A. 86:8897, 1989

10.   Bodine DM, Crosier PS, Clark SC: Effects of hematopoietic growth factors on

10   the survival of primitive stem cells in liquid suspension culture. Blood 78:914, 1991

11.   Kittler EL, Peters SO, Crittenden RB, Debatis ME, Ramshaw HS, Stewart FM, Quesenberry PJ: Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood 90:865, 1997

12.   Traycoff CM, Cornetta K, Yoder MC, Davidson A, Srour EF: Ex vivo

15   expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. Experimental Hematology 24:299, 1996

13.   Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ: Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads

20   to impaired engraftment in irradiated hosts. Blood 87:30, 1996

14.   Traycoff CM, Orazi A, Ladd AC, Rice S, McMahel J, Srour, EF: Proliferation-induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34+ cells. Experimental Hematology 26:53, 1998

25   15.   Muench MO, Firpo MT, Moore MA: Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 81:3463, 1993

16.   Flasshove M, Banerjee D, Mineishi S, Li MX, Bertino JR, Moore MA: Ex

30   vivo expansion and selection of human CD34+ peripheral blood progenitor cells after

introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer.
Blood 85:566, 1995

17.   Petzer AL, Zandstra PW, Piret JM, Eaves CJ: Differential cytokine effects on
primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand
5   and thrombopoietin. J.Exp.Med. 183:2551, 1996

18.   Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ: Self-renewal of
primitive human hematopoietic cells (long-term- culture-initiating cells) in vitro and
their expansion in defined medium. Proc.Natl.Acad.Sci.U.S.A. 93:1470, 1996

19.   Zandstra PW, Conneally E, Petzer AL, Piret JM, Eaves CJ: Cytokine
10   manipulation of primitive human hematopoietic cell self- renewal.
Proc.Natl.Acad.Sci.U.S.A. 94:4698, 1997

20.   Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T,
Moritz T, Murdoch B, Xiao XL, Kato I, Williams DA, Dick JE: Identification of
primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone
15   marrow: implications for gene therapy. Nat.Med. 2:1329, 1996

21.   Gan OI, Murdoch B, Larochelle A, Dick JE: Differential maintenance of
primitive human SCID-repopulating cells, clonogenic progenitors, and long-term
culture-initiating cells after incubation on human bone marrow stromal cells. Blood
90:641, 1997

20   22.   Bhatia M, Bonnet D, Kapp U, Wang JC, Murdoch B, Dick JE: Quantitative
analysis reveals expansion of human hematopoietic repopulating cells after short-term
ex vivo culture. J.Exp.Med. 186:619, 1997

23.   Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L:
Retrovirus-mediated expression of a DNA repair protein in bone marrow protects
25   hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer
Res. 55:2608, 1995

24.   Galipeau J, Benaim E, Spencer HT, Blakley RL, Sorrentino BP: A bicistronic
retroviral vector for protecting hematopoietic cells against antifolates and
P-glycoprotein effluxed drugs. Human Gene Therapy In Press:1997

30   25.   Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer
strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579, 1996

26.   Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579, 1996

27.   Scarpa M, Cournoyer D, Muzny DM, Moore KA, Belmont JW, Caskey CT: Characterization of recombinant helper retroviruses from Moloney- based vectors in ecotropic and amphotropic packaging cell lines. Virology 180:849, 1991

28.   Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579, 1993

29.   Williams DA: Ex vivo expansion of hematopoietic stem and progenitor cells--robbing Peter to pay Paul? [editorial]. Blood 81:3169, 1993

30.   Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A: Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood 88:1297, 1996

31.   Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85, 1991

32.   Borst P, Schinkel AH, Smit JJ, Wagenaar, van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacology & Therapeutics 60:289, 1993

33.   Schinkel AH, Borst P: Multidrug resistance mediated by P-glycoproteins. Seminars in Cancer Biology 2:213, 1991

34.   Borst P: Genetic mechanisms of drug resistance. A review. Acta Oncologica 30:87, 1991

35.   Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te RH: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491, 1994

36.   Smit JJ, Schinkel AH, Oude ER, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van, Roon MA: Homozygous disruption of the

murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451, 1993

37.   Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van, der VM, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe, WE, Borst P:

5   Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 94:4028, 1997

38.   van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while

10   MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507, 1996

39.   Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR: Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. Journal of Biological Chemistry

15   271:28753, 1996

40.   Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of Experimental Medicine 182:1545, 1995

20   41.   Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg, SS, Roepe PD: Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:11169, 1997

42.   Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP: Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant

25   human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB Journal 12:101, 1998

43.   Gruol DJ, Bourgeois S: Expression of the mdr1 P-glycoprotein gene: a mechanism of escape from glucocorticoid-induced apoptosis. Biochemistry & Cell Biology 72:561, 1994

42

44.   Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc.Natl.Acad.Sci.U.S.A. 89:9676, 1992

45.   Ward M, Richardson C, Pioli P, Smith L, Podda S, Goff S, Hesdorffer C,
5   Bank A: Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 84:1408, 1994

46.   Sorrentino BP, McDonagh KT, Woods D, Orlic D: Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86:491, 1995

10   47.   Hanania EG, Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1:21, 1994

While the invention has been described and illustrated herein by references to the
15   specific embodiments, various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and procedures selected for that purpose. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such
20   modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications in addition to the immediately foregoing are cited herein, the
25   disclosures of which are also incorporated by reference in their entireties.

43

WHAT IS CLAIMED IS:

1.   A method of performing *ex vivo* expansion of a gene-modified hematopoietic stem cell comprising:

        (a)   transducing a hematopoietic stem cell with a nucleic acid encoding MDR-1; wherein the hematopoietic stem cell is transduced to become a gene-modified hematopoietic stem cell; and

        (b)   culturing the gene-modified hematopoietic stem cell *ex vivo* wherein the gene-modified hematopoietic stem cell is expanded.

2.   The method of Claim 1 wherein said culturing is performed in the presence of an early-acting hematopoietic cytokine.

3.   The method of Claim 1 wherein the cytokine is selected from the group of cytokines consisting of interleukin-3, interleukin-6, G-CSF, GM-CSF, FLT-3 ligand, and stem cell factor.

4.   The method of Claim 1 wherein transducing the hematopoietic stem cell with a nucleic acid encoding MDR-1 is performed with a viral vector comprising a nucleic acid encoding an MDR-1.

5.   The method of Claim 4 wherein the viral vector is selected from the group of viral vectors consisting of a herpes simplex viral vector, an adenoviral vector, and adeno-associated viral vector (AAV).

6.   The method of Claim 4 wherein the viral vector is a retroviral vector.

7.   The method of Claim 6 wherein the retroviral vector is a Harvey Murine Sarcoma Vector and the hematopoietic stem cell is transduced by co-culture on retroviral producer cell lines.

44

8.   The method of Claim 1 wherein transducing the hematopoietic stem cell with a nucleic acid encoding MDR-1 is performed with a DNA vector comprising a nucleic acid encoding an MDR-1.

9.   The method of Claim 1 wherein the hematopoietic stem cell is a mammalian

5   hematopoietic stem cell.

10.   The method of Claim 9 wherein the gene-modified hematopoietic stem cell expresses a splice-corrected version of the human MDR-1.

11.   The method of Claim 9 wherein the mammalian hematopoietic stem cell is a murine hematopoietic stem cell.

10   12.   The method of Claim 9 wherein the mammalian hematopoietic stem cell is a human hematopoietic stem cell.

13.   A gene-modified mammalian hematopoietic stem cell that has been (i) transduced with a nucleic acid encoding MDR-1, and (ii) expanded.

14.   The gene-modified hematopoietic stem cell of Claim 13 that has been

15   expanded for at least 9 days.

15.   A method of engrafting a mammal with the gene-modified hematopoietic stem cell of Claim 13 comprising placing said cell into the mammal.

16.   The method of Claim 15 wherein the gene-modified hematopoietic stem cell further comprises a heterologous gene, and wherein the expression of the heterologous

20   gene by the gene-modified hematopoietic stem cell in the mammal aids in the treatment of a disease associated with a dysfunctional cell; wherein said dysfunctional cell is derived from an hematopoietic stem cell.

17.   The method of Claim 15 wherein said placing is performed by injecting.

18.   The method of Claim 17 wherein said injecting is repeated more than once.

19.   The method of Claim 15 wherein said engrafting is stable for at least six months.

5   20.   The method of Claim 15 wherein said mammal is a human.

FIG. 1B

FIG. 1A

FIG. 2C

FIG. 2D

FIG. 2A

FIG. 2B

FIG. 3B

Recipients Injected with
MDR1 Expanded Marrow

15   7   11   18   20

FIG. 3A

Non-injected
Recipient

MDR1 Transduced
Donor

MDR 20
Secondary Transplants

FIG. 3C

FIG. 3D-1
EVENTS

DHFR #1

FIG. 3D-2
EVENTS

MDR #7

FIG. 3D-3
EVENTS

MDR #11

FIG. 3D-4
EVENTS

MDR #18

FIG. 3D-5
EVENTS

MDR #20

PgP Fluoresence

FIG. 4

Donor cells	C57 vs. HW80	HW80 vs. C57	C57 vs. HW80
Vector:Days Expansion	MDR:12 vs. None:0	DHFR:12 vs.None:0	MDR:12 vs. DHFR:12
Fraction Hind Limbs Vol.	0.005 vs. 0.25	0.005 vs.0.25	0.005 vs. 0.005

% C57 Donor Reconstitution

FIG. 5

Representative Secondary Day 12 CFU-S

Negative Control CFU-S

FIG. 6A

Days of Expansion for MDR1
Transduced HW80 Marrow

FIG. 6B

FIG. 7A

FIG. 7B-2
Normal

FIG. 7B-4
Abnormal

FIG. 7B-6
Abnormal

Magnification

50x

10x

FIG. 7B-1
Normal

FIG. 7B-3
Abnormal

FIG. 7B-5
Abnormal

SEQUENCE LISTING

<110> SORRENTINO ET AL.

<120> EXPANSION OF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH

MDR-1 METHODS OF USE THEREOF

<130> 1340-1-021PCT

<140> 1340-1-21

<141> 1999-05-27

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 3860

<212> DNA

<213> HUMAN MDR 185-G

<400> 1

atggatcttg aaggggaccg caatggagga gcaaagaaga agaacttttt taaactgaac 60

aataaaagtg aaaaagataa gaaggaaaag aaaccaactg tcagtgtatt ttcaatgttt 120

cgctattcaa attggcttga caagttgtat atggtggtgg gaactttggc tgccatcatc 180

catgggctg gacttcctct catgatgctg gtgtttggag aaatgacaga tatctttgca 240

aatgcaggaa atttagaaga tctgatgtca aacatcacta tagaagtga tatcaatgat 300

acagggttct tcatgaatct ggaggaagac atgaccagat atgcctatta ttacagtgga 360

attggtgctg gggtgctggt tgctgcttac attcaggttt cattttggtg cctggcagct 420

```
ggaagacaaa tacacaaaat tagaaaacag tttttcatg ctataatgcg acaggagata 480

ggctggtttg atgtgcacga tgttggggag cttaacaccc gacttacaga tgatgtctct 540

aagattaatg aaggtattgg tgacaaaatt ggaatgttct ttcagtcaat ggcaacattt 600

ttcactgggt ttatagtagg atttacacgt ggttggaagc taacccttgt gattttggcc 660

atcagtcctg ttcttggact gtcagctgct gtctgggcaa agatactatc ttcatttact 720

gataaagaac tcttagcgta tgcaaaagct ggagcagtag ctgaagaggt cttggcagca 780

attagaactg tgattgcatt tggaggacaa aagaaagaac ttgaaaggta caacaaaaat 840

ttagaagaag ctaaaagaat tgggataaag aaagctatta cagccaatat ttctataggt 900

gctgctttcc tgctgatcta tgcatcttat gctctggcct tctggtatgg gaccaccttg 960

gtcctctcag gggaatattc tattggacaa gtactcactg tattcttttc tgtattaatt 1020

ggggctttta gtgttggaca ggcatctcca agcattgaag catttgcaaa tgcaagagga 1080

gcagcttatg aaatcttcaa gataattgat aataagccaa gtattgacag ctattcgaag 1140

agtgggcaca aaccagataa tattaaggga aatttggaat tcagaaatgt tcacttcagt 1200

tacccatctc gaaaagaagt taagatcttg aagggcctga acctgaaggt gcagagtggg 1260

cagacggtgg ccctggttgg aaacagtggc tgtgggaaga gcacaacagt ccagctgatg 1320

cagaggctct atgaccccac agaggggatg gtcagtgttg atggacagga tattaggacc 1380

ataaatgtaa ggtttctacg ggaaatcatt ggtgtggtga gtcaggaacc tgtattgctt 1440

gccaccacga tagctgaaaa cattcgctat ggccgtgaaa atgtcaccat ggatgagatt 1500

gagaaagctg tcaaggaagc caatgcctat gactttatca tgaaactgcc tcataaattt 1560

gacaccctgg ttggagagag aggggcccag ttgagtggtg ggcagaagca gaggatcgcc 1620

attgcacgtg ccctggttcg caaccccaag atcctcctgc tggatgaggc cacgtcagcc 1680

ttggacacag aaagcgaagc agtggttcag gtggctctgg ataaggccag aaaaggtcgg 1740

accaccattg tgatagctca tcgtttgtct acagttcgta atgctgacgt catcgctggt 1800

ttcgatgatg gagtcattgt ggagaaagga aatcatgatg aactcatgaa agagaaaggc 1860

atttacttca aacttgtcac aatgcagaca gcaggaaatg aagttgaatt agaaaatgca 1920

gctgatgaat ccaaaagtga aattgatgcc ttggaaatgt cttcaaatga ttcaagatcc 1980

agtctaataa gaaaaagatc aactcgtagg agtgtccgtg atcacaagc ccaagacaga 2040

aagcttagta ccaaagaggc tctggatgaa agtatacctc cagtttcctt ttggaggatt 2100

atgaagctaa atttaactga atggccttat tttgttgttg gtgtattttg tgccattata 2160
```

2

```
aatggaggcc tgcaaccagc atttgcaata atattttcaa agattatagg ggtttttaca 2220

agaattgatg atcctgaaac aaaacgacag aatagtaact tgttttcact attgtttcta 2280

gcccttggaa ttatttcttt tattacattt ttccttcaag gtttcacatt tggcaaagct 2340

ggagagatcc tcaccaagcg gctccgatac atggttttcc gatccatgct cagacaggat 2400

gtgagttggt ttgatgaccc taaaaacacc actggagcat tgactaccag gctcgccaat 2460

gatgctgctc aagttaaagg ggctataggt tccaggcttg ctgtaattac ccagaatata 2520

gcaaatcttg ggacaggaat aattatatcc ttcatctatg gttggcaact aacactgtta 2580

ctcttagcaa ttgtacccat cattgcaata gcaggagttg ttgaaatgaa aatgttgtct 2640

ggacaagcac tgaaagataa gaaagaacta gaaggtgctg ggaagatcgc tactgaagca 2700

atagaaaact tccgaaccgt tgtttctttg actcaggagc agaagtttga acatatgtat 2760

gctcagagtt tgcaggtacc atacagaaac tctttgagga aagcacacat ctttggaatt 2820

acattttcct tcacccaggc aatgatgtat ttttcctatg ctggatgttt ccggtttgga 2880

gcctacttgg tggcacataa actcatgagc tttgaggatg ttctgttagt attttcagct 2940

gttgtctttg gtgccatggc cgtggggcaa gtcagttcat ttgctcctga ctatgccaaa 3000

gccaaaatat cagcagccca catcatcatg atcattgaaa aaacccccttt gattgacagc 3060

tacagcacgg aaggcctaat gccgaacaca ttggaaggaa atgtcacatt tggtgaagtt 3120

gtattcaact atcccacccg accggacatc ccagtgcttc agggactgag cctggaggtg 3180

aagaagggcc agacgctggc tctggtgggc agcagtggct gtgggaagag cacagtggtc 3240

cagctcctgg agcggttcta cgaccccttg gcagggaaag tgctgcttga tggcaaagaa 3300

ataaagcgac tgaatgttca gtggctccga gcacacctgg gcatcgtgtc ccaggagccc 3360

atcctgtttg actgcagcat tgctgagaac attgcctatg gagacaacag ccgggtggtg 3420

tcacaggaag agatcgtgag ggcagcaaag gaggccaaca tacatgcctt catcgagtca 3480

ctgcctaata aatatagcac taaagtagga gacaaaggaa ctcagctctc tggtggccag 3540

aaacaacgca ttgccatagc tcgtgccctt gttagacagc ctcatatttt gcttttggat 3600

gaagccacgt cagctctgga tacagaaagt gaaaaggttg tccaagaagc cctggacaaa 3660

gccagagaag ccgcacctg cattgtgatt gctcaccgcc tgtccaccat ccagaatgca 3720

gacttaatag tggtgtttca gaatggcaga gtcaaggagc atggcacgca tcagcagctg 3780

ctggcacaga aaggcatcta tttttcaatg gtcagtgtcc aggctggaac aaagcgccag 3840

tgaactctgg ttaactccac                                             3860
```

                                        3

<210> 2

<211> 1280

<212> PRT

<213> HUMAN MDR 185-G

<400> 2

Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe

1   5   10   15

Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro

            20   25   30

Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys

        35   40   45

Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly

    50   55   60

Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala

65   70   75   80

Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser

            85   90   95

Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr

            100   105   110

Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala

4

                115   120   125

Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
        130   135   140

His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
145   150   155   160

Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
                165   170   175

Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile Gly Met
            180   185   190

Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
        195   200   205

Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
    210   215   220

Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
225   230   235   240

Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
                245   250   255

Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys
                260   265   270

                                    5

Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
            275   280   285

Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
            290   295   300

Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
305   310   315   320

Val Leu Ser Gly Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe
            325   330   335

Ser Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile
            340   345   350

Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile
            355   360   365

Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys
            370   375   380

Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser
385   390   395   400

Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys
            405   410   415

Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly
            420   425   430

6

Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu
        435   440   445

Gly Met Val Ser Val Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg
        450   455   460

Phe Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe
465   470   475   480

Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn Val Thr
                485   490   495

Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe
            500   505   510

Ile Met Lys Leu Pro His Lys Phe Asp Thr Leu Val Gly Glu Arg Gly
            515   520   525

Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala
        530   535   540

Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala
545   550   555   560

Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala
                565   570   575

Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val

7

```
          580                    585                    590


Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu
     595                    600                    605


Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys
     610                    615                    620


Leu Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala
625                    630                    635                    640


Ala Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn
               645                    650                    655


Asp Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val
               660                    665                    670


Arg Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu
               675                    680                    685


Asp Glu Ser Ile Pro Pro Val Ser Phe Trp Arg Ile Met Lys Leu Asn
     690                    695                    700


Leu Thr Glu Trp Pro Tyr Phe Val Val Gly Val Phe Cys Ala Ile Ile
705                    710                    715                    720


Asn Gly Gly Leu Gln Pro Ala Phe Ala Ile Ile Phe Ser Lys Ile Ile
               725                    730                    735
```

8

Gly Val Phe Thr Arg Ile Asp Asp Pro Glu Thr Lys Arg Gln Asn Ser
          740   745   750

Asn Leu Phe Ser Leu Leu Phe Leu Ala Leu Gly Ile Ile Ser Phe Ile
          755   760   765

Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu
        770   775   780

Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln Asp
785   790   795   800

Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr
                805   810   815

Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser Arg
          820   825   830

Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile
          835   840   845

Ile Ser Phe Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Leu Ala Ile
          850   855   860

Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser
865   870   875   880

Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys Ile
          885   890   895

9

Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Gln
          900   905   910

Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr
          915   920   925

Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe
          930   935   940

Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly
945   950   955   960

Ala Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu
          965   970   975

Val Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser
          980   985   990

Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile
          995   1000   1005

Ile Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu
          1010   1015   1020

Gly Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val
1025   1030   1035   1040

Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu

10

                    1045   1050   1055

Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser
            1060   1065   1070

Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp
        1075   1080   1085

Pro Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu
        1090   1095   1100

Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro
1105   1110   1115   1120

Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn
            1125   1130   1135

Ser Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala
            1140   1145   1150

Asn Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys
        1155   1160   1165

Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile
        1170   1175   1180

Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp
1185   1190   .   1195   1200

Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu

    1205   1210   1215

Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His

    1220   1225   1230

Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn

    1235   1240   1245

Gly Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys

   1250   1255   1260

Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln

1265   1270   1275   1280

<210> 3

<211> 3860

<212> DNA

<213> HUMAN MDR 185-V

<400> 3

atggatcttg aaggggaccg caatggagga gcaaagaaga agaactttt taaactgaac 60

aataaaagtg aaaaagataa gaaggaaaag aaaccaactg tcagtgtatt ttcaatgttt 120

cgctattcaa attggcttga caagttgtat atggtggtgg gaactttggc tgccatcatc 180

catggggctg gacttcctct catgatgctg gtgtttggag aaatgacaga tatcctttgca 240

12

```
aatgcaggaa atttagaaga tctgatgtca aacatcacta atagaagtga tatcaatgat 300

acagggttct tcatgaatct ggaggaagac atgaccagat atgcctatta ttacagtgga 360

attggtgctg gggtgctggt tgctgcttac attcaggttt cattttggtg cctggcagct 420

ggaagacaaa tacacaaaat tagaaaacag tttttttcatg ctataatgcg acaggagata 480

ggctggtttg atgtgcacga tgttggggag cttaacaccc gacttacaga tgatgtctct 540

aagattaatg aagttattgg tgacaaaatt ggaatgttct ttcagtcaat ggcaacattt 600

ttcactgggt ttatagtagg atttacacgt ggttggaagc taacccttgt gattttggcc 660

atcagtcctg ttcttggact gtcagctgct gtctgggcaa agatactatc ttcatttact 720

gataaagaac tcttagcgta tgcaaaagct ggagcagtag ctgaagaggt cttggcagca 780

attagaactg tgattgcatt tggaggacaa aagaaagaac ttgaaaggta caacaaaaat 840

ttagaagaag ctaaaagaat tgggataaag aaagctatta cagccaatat ttctataggt 900

gctgctttcc tgctgatcta tgcatcttat gctctggcct tctggtatgg gaccaccttg 960

gtcctctcag gggaatattc tattggacaa gtactcactg tattctttttc tgtattaatt 1020

ggggcttttta gtgttggaca ggcatctcca agcattgaag catttgcaaa tgcaagagga 1080

gcagcttatg aaatcttcaa gataattgat aataagccaa gtattgacag ctattcgaag 1140

agtgggcaca aaccagataa tattaaggga aatttggaat tcagaaatgt tcacttcagt 1200

tacccatctc gaaaagaagt taagatcttg aagggcctga acctgaaggt gcagagtggg 1260

cagacggtgg ccctggttgg aaacagtggc tgtgggaaga gcacaacagt ccagctgatg 1320

cagaggctct atgaccccac agaggggatg gtcagtgttg atggacagga tattaggacc 1380

ataaatgtaa ggtttctacg ggaaatcatt ggtgtggtga gtcaggaacc tgtattgttt 1440

gccaccacga tagctgaaaa cattcgctat ggccgtgaaa atgtcaccat ggatgagatt 1500

gagaaagctg tcaaggaagc caatgcctat gactttatca tgaaactgcc tcataaattt 1560

gacaccctgg ttggagagag aggggcccag ttgagtggtg ggcagaagca gaggatcgcc 1620

attgcacgtg ccctggttcg caacccaag atcctcctgc tggatgaggc cacgtcagcc 1680

ttggacacag aaagcgaagc agtggttcag gtggctctgg ataaggccag aaaaggtcgg 1740

accaccattg tgatagctca tcgtttgtct acagttcgta atgctgacgt catcgctggt 1800

ttcgatgatg gagtcattgt ggagaaagga aatcatgatg aactcatgaa agagaaaggc 1860

atttacttca aacttgtcac aatgcagaca gcaggaaatg aagttgaatt agaaaatgca 1920

gctgatgaat ccaaaagtga aattgatgcc ttggaaatgt cttcaaatga ttcaagatcc 1980
```

13

agtctaataa gaaaaagatc aactcgtagg agtgtccgtg gatcacaagc ccaagacaga 2040

aagcttagta ccaaagaggc tctggatgaa agtatacctc cagtttcctt ttggaggatt 2100

atgaagctaa atttaactga atggccttat tttgttgttg gtgtattttg tgccattata 2160

aatggaggcc tgcaaccagc atttgcaata atattttcaa agattatagg ggttttttaca 2220

agaattgatg atcctgaaac aaaacgacag aatagtaact tgttttcact attgtttcta 2280

gcccttggaa ttatttcttt tattacattt ttccttcaag gtttcacatt tggcaaagct 2340

ggagagatcc tcaccaagcg gctccgatac atggttttcc gatccatgct cagacaggat 2400

gtgagttggt ttgatgaccc taaaaacacc actggagcat tgactaccag gctcgccaat 2460

gatgctgctc aagttaaagg ggctataggt tccaggcttg ctgtaattac ccagaatata 2520

gcaaatcttg ggacaggaat aattatatcc ttcatctatg gttggcaact aacactgtta 2580

ctcttagcaa ttgtacccat cattgcaata gcaggagttg ttgaaatgaa aatgttgtct 2640

ggacaagcac tgaaagataa gaaagaacta gaaggtgctg ggaagatcgc tactgaagca 2700

atagaaaact tccgaaccgt tgtttctttg actcaggagc agaagtttga acatatgtat 2760

gctcagagtt tgcaggtacc atacagaaac tctttgagga aagcacacat ctttggaatt 2820

acattttcct tcacccaggc aatgatgtat ttttcctatg ctggatgttt ccggtttgga 2880

gcctacttgg tggcacataa actcatgagc tttgaggatg ttctgttagt attttcagct 2940

gttgtctttg gtgccatggc cgtggggcaa gtcagttcat ttgctcctga ctatgccaaa 3000

gccaaaatat cagcagccca catcatcatg atcattgaaa aaacccctt gattgacagc 3060

tacagcacgg aaggcctaat gccgaacaca ttggaaggaa atgtcacatt tggtgaagtt 3120

gtattcaact atcccacccg accggacatc ccagtgcttc agggactgag cctggaggtg 3180

aagaagggcc agacgctggc tctggtgggc agcagtggct gtgggaagag cacagtggtc 3240

cagctcctgg agcggttcta cgaccccttg gcagggaaag tgctgcttga tggcaaagaa 3300

ataaagcgac tgaatgttca gtggctccga gcacacctgg gcatcgtgtc ccaggagccc 3360

atcctgtttg actgcagcat tgctgagaac attgcctatg gagacaacag ccgggtggtg 3420

tcacaggaag agatcgtgag ggcagcaaag gaggccaaca tacatgcctt catcgagtca 3480

ctgcctaata aatatagcac taaagtagga gacaaaggaa ctcagctctc tggtggccag 3540

aaacaacgca ttgccatagc tcgtgccctt gttagacagc ctcatatttt gcttttggat 3600

gaagccacgt cagctctgga tacagaaagt gaaaaggttg tccaagaagc cctggacaaa 3660

gccagagaag ccgcacctg cattgtgatt gctcaccgcc tgtccaccat ccagaatgca 3720

14

gacttaatag tggtgtttca gaatggcaga gtcaaggagc atggcacgca tcagcagctg 3780

ctggcacaga aaggcatcta tttttcaatg gtcagtgtcc aggctggaac aaagcgccag 3840

tgaactctgg ttaactccac   3860

<210> 4

<211> 1280

<212> PRT

<213> HUMAN MDR 185-V

<400> 4

Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe

  1   5   10   15

Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro

         20   25   30

Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys

        35   40   45

Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly

     50   55   60

Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala

 65   70   75   80

Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser

        85   90   95

Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr

                    100   105   110

Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
          115   120   125

Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
     130   135   140

His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
145   150   155   160

Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
               165   170   175

Asp Asp Val Ser Lys Ile Asn Glu Val Ile Gly Asp Lys Ile Gly Met
               180   185   190

Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
          195   200   205

Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
     210   215   220

Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
225   230   235   240

Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
               245   250   255

16

Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys
         260   265   270

Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
        275   280   285

Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
        290   295   300

Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
305   310   315   320

Val Leu Ser Gly Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe
        325   330   335

Ser Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile
        340   345   350

Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile
        355   360   365

Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys
        370   375   380

Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser
385   390   395   400

Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys
        405   410   415

17

Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly
            420   425   430

Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu
            435   440   445

Gly Met Val Ser Val Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg
            450   455   460

Phe Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe
465   470   475   480

Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn Val Thr
            485   490   495

Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe
            500   505   510

Ile Met Lys Leu Pro His Lys Phe Asp Thr Leu Val Gly Glu Arg Gly
            515   520   525

Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala
            530   535   540

Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala
545   550   555   560

Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala

18

                        565   570   575

Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val
          580   585   590

Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu
          595   600   605

Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys
          610   615   620

Leu Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala
625   630   635   640

Ala Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn
                 645   650   655

Asp Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val
          660   665   670

Arg Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu
          675   680   685

Asp Glu Ser Ile Pro Pro Val Ser Phe Trp Arg Ile Met Lys Leu Asn
          690   695   700

Leu Thr Glu Trp Pro Tyr Phe Val Val Gly Val Phe Cys Ala Ile Ile
705   710   715   720

                                19

Asn Gly Gly Leu Gln Pro Ala Phe Ala Ile Ile Phe Ser Lys Ile Ile
                725   730   735

Gly Val Phe Thr Arg Ile Asp Asp Pro Glu Thr Lys Arg Gln Asn Ser
          740   745   750

Asn Leu Phe Ser Leu Leu Phe Leu Ala Leu Gly Ile Ile Ser Phe Ile
          755   760   765

Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu
       770   775   780

Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln Asp
785   790   795   800

Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr
                805   810   815

Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser Arg
          820   825   830

Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile
          835   840   845

Ile Ser Phe Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Leu Ala Ile
       850   855   860

Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser
865   870   875   880

20

Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys Ile
            885   890   895

Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Gln
            900   905   910

Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr
        915   920   925

Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe
        930   935   940

Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly
945   950   955   960

Ala Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu
            965   970   975

Val Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser
            980   985   990

Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile
            995   1000   1005

Ile Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu
    1010   1015   1020

Gly Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val

21

1025   1030   1035   1040

Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu
           1045   1050   1055

Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser
           1060   1065   1070

Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp
        1075   1080   1085

Pro Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu
        1090   1095   1100

Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro
1105   1110   1115   1120

Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn
           1125   1130   1135

Ser Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala
           1140   1145   1150

Asn Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys
           1155   1160   1165

Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile
        1170   1175   1180

Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp
1185   1190   1195   1200

Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu
                       1205   1210   1215

Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His
                       1220   1225   1230

Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn
                       1235   1240   1245

Gly Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys
                       1250   1255   1260

Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln
1265   1270   1275   1280

<210> 5

<211> 4189

<212> DNA

<213> MOUSE MDR-1

<400> 5

atggagtttg aagagaacct taagggaaga gcagacaaga acttctcgaa gatgggcaaa 60

aagagtaaaa aggagaagaa agaaaagaaa cctgctgttg gcgtatttgg gatgtttcgc 120

tatgcagatt ggctggacaa gctgtgcatg attctgggaa ctctcgctgc tattatccat 180

ggaacattac ttcccctctt gatgctggtg tttggaaaca tgacagatag ttttacaaaa 240

gcagaagcca gtattctgcc aagcattact aatcaaagtg gacccaacag tactctgatc 300

atcagcaaca gcagtctgga ggaagagatg gccatatacg cctactatta caccgggatt 360

ggtgctggtg tgctcatagt tgcctacatc caggtttcac tttggtgcct ggcagctgga 420

agacagatac acaagattag gcagaagttt ttccatgcta taatgaatca ggagataggc 480

tggtttgatg tgcatgatgt tggggagctc aacacccggc tcacagatga tgtctccaaa 540

attaatgacg gaattggtga caaaattggg atgttttttc agtccataac cacattttta 600

gccggtttta tcataggatt tataagtggt tggaagctaa cccttgtcat tttggctgtc 660

agccctctta ttggattgtc atctgctttg tgggcaaagg tattgacttc atttactaat 720

aaggaactcc aggcttatgc aaaagctgga gcagttgctg aagaagtctt agcagccatc 780

agaactgtga ttgcctttgg aggacaacag aaggaacttg aaaggtacaa taaaaattta 840

gaagaagcta aaaatgttgg cataaagaaa gctatcacag ccagcatttc gataggcatt 900

gcctacctgt tggtctatgc atcatatgca ctggcattct ggtatgggac atccttggtc 960

ctctcaaatg aatattctat tggagaagtg cttactgtct tcttctctat tttgttgggg 1020

acttttagta ttggacactt ggccccaaac atagaagcct ttgcaaacgc acgaggggca 1080

gcctttgaaa tcttcaagat aattgataac gagccaagca ttgacagctt ctcaacaaag 1140

ggctacaaac cagacagtat aatgggaaac ttagagttta aaaatgttca cttcaactac 1200

ccatcgagaa gcgaagttca gatcttgaag ggcctcaatc tgaaggtgaa gagcggacag 1260

acggtggcct tggttggcaa cagtggctgt ggaaaaagca caactgtcca gctgatgcag 1320

aggctctacg accccctgga gggcgtggtc agtatcgacg gacaagacat cagaaccatc 1380

aatgtgaggt atctgaggga gatcattggt gtggtgagtc aggaacctgt gctgtttgcc 1440

accacgatcg ccgagaacat tcgctatggc cgagaagatg tcaccatgga tgagattgag 1500

aaagctgtca aggaagccaa tgcctatgac ttcatcatga actgccccca ccaatttgac 1560

accctggttg gtgagagagg ggcgcagctg agtggggggac agaaacagag aatcgccatt 1620

gcccgggccc tggtccgcaa tcccaagatc cttttgttgg acgaggccac ctcagccctg 1680

gatacagaaa gtgaagctgt ggtgcaggcc gcactggata aggctagaga aggccggacc 1740

accattgtga tagctcatcg cttgtctaca gttcgtaatg ctgacgtcat tgctggtttt 1800

24

```
gatggtggtg tcattgtgga gcaaggaaat catgatgagc tcatgagaga aaagggcatt 1860

tacttcaaac ttgtcatgac acagactaga ggaaatgaaa ttgaaccagg aaataatgct 1920

tatggatccc agagtgacac tgatgcttct gaactgactt cagaagaatc caaatcacct 1980

ttaataagga gatcaattta cagaagtgtc cacagaaagc aagaccaaga gagaagactt 2040

agtatgaaag aggctgtgga tgaagatgtg cctctggttt ccttttggcg gatcctaaat 2100

ctaaatctaa gtgaatggcc ttatttactt gttggcgtac tttgcgctgt tataaatggg 2160

tgcatacaac cagtgtttgc catagtattt tcaaggattg taggggtttt ttcaagagat 2220

gatgaccatg aaactaaacg acagaattgt aatttgtttt ccctgttctt tctggttatg 2280

gggctgattt ctttgttac atattcttt cagggcttca catttggcaa agccggagag 2340

atcctcacca agcgagtccg atacatggtt ttcaaatcca tgctgagaca ggatataagc 2400

tggttcgatg accataagaa cagcactggc tcactgacca ccaggctcgc cagtgatgct 2460

tctagtgtta aaggggcgat gggcgccagg cttgctgtag ttacccagaa tgtagcaaac 2520

ctcgggacag gagtcatcct ctccttagtc tatggctggc agctgacact tctacttgta 2580

gtaattatac cgctcattgt attgggcgga attattgaaa tgaagctgtt gtctggccaa 2640

gccttgaagg acaagaaaca gcttgagatc tctgggaaga ttgctacaga agcaattgaa 2700

aacttccgca ctattgtctc tttgactcgg gagcagaagt ttgaaaccat gtatgcccag 2760

agcttgcagg taccatacag aaatgcgatg aagaaagcac acgtgtttgg gatcacgttc 2820

tccttcaccc aggccatgat gtatttttct tatgctgctt gtttccggtt cggtgcctac 2880

ttggtggcac aacaactcat gacttttgaa aatgttatgt tggtattttc tgctgttgtc 2940

tttggtgcca tggcagctgg gaatactagt tcatttgctc ctgactatgc gaaagccaaa 3000

gtatcagcat ctcatatcat caggatcatt gagaaaaccc ctgagattga cagctacagc 3060

acagagggct tgaagcctac tctgttagaa ggaaatgtaa aatttaatgg agtccagttt 3120

aactatccca cccgacccaa catcccagtg cttcaggggc tgagcctcga ggtgaagaag 3180

ggccagacgt tggccctggt gggcagcagt ggctgtggga agagcacagt ggtccagctg 3240

ctcgagcgct tctacgaccc catggctgga tcagtgtttc tagatggcaa agaaataaag 3300

caactgaatg tccagtggct ccgagctcac cttggcattg tgtcccagga gcccattctc 3360

tttgactgca gcattgcaga gaacatcgcc tatggagaca acagccgggc cgtgtctcat 3420

gaggagattg tgagggcagc caaggaggcc aacatccacc agttcatcga ctcactgcct 3480

gataaataca acaccagagt aggagacaaa ggcactcagc tgtcgggtgg gcagaagcag 3540
```

25

cgcatcgcca tcgcacgtgc cctcgtcaga cagcctcaca ttttacttct ggacgaagca 3600

acatcagctc tggatacaga aagtgaaaag gttgtccagg aagcgctgga caaagccagg 3660

gaaggccgca cctgcattgt gatcgctcac cgcctgtcca ccatccagaa cgcggacttg 3720

atcgtggtga ttgagaacgg caaagtcaag gagcacggca cccaccagca gctgctggcg 3780

cagaagggca tctacttctc aatggtccag gctggagcaa agcgctcatg agctgtgact 3840

atctgaggtg ctaagtattt ttaatattgg tgtttaaaca tggcaccaaa ccaaagttaa 3900

aaggcaaggg ctgttaaagg taactccatc aagatgagaa gccttccgag actttgtaat 3960

taaatgaacc aaaatcggaa acaaacaaac aaacaaacaa acaagccata gttaaacagg 4020

gccatgtttt taattgcatt acgtgattca taagagaaca tatagttttt taaaataaaa 4080

tgtataattt tgtttcagtt tttaatttct accctacttt cttaaatgat tataaagatt 4140

gtaaaaagca ctatttctta aattgcctat aaaaattaaa ttttcatat   4189

<210> 6

<211> 1276

<212> PRT

<213> MOUSE MDR-1

<400> 6

Met Glu Phe Glu Glu Asn Leu Lys Gly Arg Ala Asp Lys Asn Phe Ser

1   5   10   15

Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys Pro Ala

            20   25   30

Val Gly Val Phe Gly Met Phe Arg Tyr Ala Asp Trp Leu Asp Lys Leu

        35   40   45

Cys Met Ile Leu Gly Thr Leu Ala Ala Ile Ile His Gly Thr Leu Leu

    50   55   60

Pro Leu Leu Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Thr Lys
65   70   75   80

Ala Glu Ala Ser Ile Leu Pro Ser Ile Thr Asn Gln Ser Gly Pro Asn
                  85   90   95

Ser Thr Leu Ile Ile Ser Asn Ser Ser Leu Glu Glu Glu Met Ala Ile
            100   105   110

Tyr Ala Tyr Tyr Tyr Thr Gly Ile Gly Ala Gly Val Leu Ile Val Ala
            115   120   125

Tyr Ile Gln Val Ser Leu Trp Cys Leu Ala Ala Gly Arg Gln Ile His
            130   135   140

Lys Ile Arg Gln Lys Phe Phe His Ala Ile Met Asn Gln Glu Ile Gly
145   150   155   160

Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr Asp
            165   170   175

Asp Val Ser Lys Ile Asn Asp Gly Ile Gly Asp Lys Ile Gly Met Phe
            180   185   190

Phe Gln Ser Ile Thr Thr Phe Leu Ala Gly Phe Ile Ile Gly Phe Ile
            195   200   205

Ser Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Val Ser Pro Leu Ile

27

                    210   215   220

Gly Leu Ser Ser Ala Leu Trp Ala Lys Val Leu Thr Ser Phe Thr Asn
225   230   235   240

Lys Glu Leu Gln Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu Val
                    245   250   255

Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Gln Lys Glu
                    260   265   270

Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Asn Val Gly Ile
                    275   280   285

Lys Lys Ala Ile Thr Ala Ser Ile Ser Ile Gly Ile Ala Tyr Leu Leu
                    290   295   300

Val Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Ser Leu Val
305   310   315   320

Leu Ser Asn Glu Tyr Ser Ile Gly Glu Val Leu Thr Val Phe Phe Ser
                    325   330   335

Ile Leu Leu Gly Thr Phe Ser Ile Gly His Leu Ala Pro Asn Ile Glu
                    340   345   350

Ala Phe Ala Asn Ala Arg Gly Ala Ala Phe Glu Ile Phe Lys Ile Ile
                    355   360   365

Asp Asn Glu Pro Ser Ile Asp Ser Phe Ser Thr Lys Gly Tyr Lys Pro
        370   375   380

Asp Ser Ile Met Gly Asn Leu Glu Phe Lys Asn Val His Phe Asn Tyr
385   390   395   400

Pro Ser Arg Ser Glu Val Gln Ile Leu Lys Gly Leu Asn Leu Lys Val
                405   410   415

Lys Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly Lys
            420   425   430

Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Leu Glu Gly
        435   440   445

Val Val Ser Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg Tyr
    450   455   460

Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe Ala
465   470   475   480

Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asp Val Thr Met
            485   490   495

Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe Ile
            500   505   510

Met Lys Leu Pro His Gln Phe Asp Thr Leu Val Gly Glu Arg Gly Ala
        515   520   525

29

Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu

530   535   540

Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu

545   550   555   560

Asp Thr Glu Ser Glu Ala Val Val Gln Ala Ala Leu Asp Lys Ala Arg

                565   570   575

Glu Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val Arg

              580   585   590

Asn Ala Asp Val Ile Ala Gly Phe Asp Gly Gly Val Ile Val Glu Gln

         595   600   605

Gly Asn His Asp Glu Leu Met Arg Glu Lys Gly Ile Tyr Phe Lys Leu

         610   615   620

Val Met Thr Gln Thr Arg Gly Asn Glu Ile Glu Pro Gly Asn Asn Ala

625   630   635   640

Tyr Gly Ser Gln Ser Asp Thr Asp Ala Ser Glu Leu Thr Ser Glu Glu

              645   650   655

Ser Lys Ser Pro Leu Ile Arg Arg Ser Ile Tyr Arg Ser Val His Arg

         660   665   670

Lys Gln Asp Gln Glu Arg Arg Leu Ser Met Lys Glu Ala Val Asp Glu

30

            675   680   685

Asp Val Pro Leu Val Ser Phe Trp Arg Ile Leu Asn Leu Asn Leu Ser
    690   695   700

Glu Trp Pro Tyr Leu Leu Val Gly Val Leu Cys Ala Val Ile Asn Gly
705   710   715   720

Cys Ile Gln Pro Val Phe Ala Ile Val Phe Ser Arg Ile Val Gly Val
                725   730   735

Phe Ser Arg Asp Asp Asp His Glu Thr Lys Arg Gln Asn Cys Asn Leu
                740   745   750

Phe Ser Leu Phe Phe Leu Val Met Gly Leu Ile Ser Phe Val Thr Tyr
                755   760   765

Phe Phe Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr Lys
    770   775   780

Arg Val Arg Tyr Met Val Phe Lys Ser Met Leu Arg Gln Asp Ile Ser
785   790   795   800

Trp Phe Asp Asp His Lys Asn Ser Thr Gly Ser Leu Thr Thr Arg Leu
                805   810   815

Ala Ser Asp Ala Ser Ser Val Lys Gly Ala Met Gly Ala Arg Leu Ala
    820   825   830

31

Val Val Thr Gln Asn Val Ala Asn Leu Gly Thr Gly Val Ile Leu Ser

     835   840   845

Leu Val Tyr Gly Trp Gln Leu Thr Leu Leu Val Val Ile Ile Pro

    850   855   860

Leu Ile Val Leu Gly Gly Ile Ile Glu Met Lys Leu Leu Ser Gly Gln

865   870   875   880

Ala Leu Lys Asp Lys Lys Gln Leu Glu Ile Ser Gly Lys Ile Ala Thr

        885   890   895

Glu Ala Ile Glu Asn Phe Arg Thr Ile Val Ser Leu Thr Arg Glu Gln

      900   905   910

Lys Phe Glu Thr Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr Arg Asn

     915   920   925

Ala Met Lys Lys Ala His Val Phe Gly Ile Thr Phe Ser Phe Thr Gln

    930   935   940

Ala Met Met Tyr Phe Ser Tyr Ala Ala Cys Phe Arg Phe Gly Ala Tyr

945   950   955   960

Leu Val Ala Gln Gln Leu Met Thr Phe Glu Asn Val Met Leu Val Phe

        965   970   975

Ser Ala Val Val Phe Gly Ala Met Ala Ala Gly Asn Thr Ser Ser Phe

        980   985   990

Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ser His Ile Ile Arg
       995   1000   1005

Ile Ile Glu Lys Thr Pro Glu Ile Asp Ser Tyr Ser Thr Glu Gly Leu
    1010   1015   1020

Lys Pro Thr Leu Leu Glu Gly Asn Val Lys Phe Asn Gly Val Gln Phe
1025   1030   1035   1040

Asn Tyr Pro Thr Arg Pro Asn Ile Pro Val Leu Gln Gly Leu Ser Leu
           1045   1050   1055

Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser Gly Cys
           1060   1065   1070

Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp Pro Met
       1075   1080   1085

Ala Gly Ser Val Phe Leu Asp Gly Lys Glu Ile Lys Gln Leu Asn Val
    1090   1095   1100

Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro Ile Leu
1105   1110   1115   1120

Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn Ser Arg
           1125   1130   1135

Ala Val Ser His Glu Glu Ile Val Arg Ala Ala Lys Glu Ala Asn Ile

33

                    1140   1145   1150

His Gln Phe Ile Asp Ser Leu Pro Asp Lys Tyr Asn Thr Arg Val Gly
        1155   1160   1165

Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile
     1170   1175   1180

Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu Ala
1185   1190   1195   1200

Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala Leu
             1205   1210   1215

Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg Leu
             1220   1225   1230

Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Ile Glu Asn Gly Lys
         1235   1240   1245

Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly Ile
     1250   1255   1260

Tyr Phe Ser Met Val Gln Ala Gly Ala Lys Arg Ser
1265   1270   1275

<210> 7

<211> 4788

                                    34

<212> DNA

<213> MOUSE MDR-3

<400> 7

atggaacttg aagaggacct taagggaaga gcagacaaga acttctcaaa gatgggcaaa 60

aagagtaaaa aggagaagaa agaaaagaaa ccagcagtca gtgtgcttac aatgtttcgt 120

tatgcaggtt ggctagacag gttgtacatg ctggtgggaa ctctggctgc tattatccat 180

ggagtggcgc tcccacttat gatgctgatc tttggtgaca tgacagatag ctttgcaagt 240

gtaggaaacg tctctaaaaa cagtactaat atgagtgagg ccgataaaag agccatgttt 300

gccaaactgg aggaagaaat gaccacgtac gcctactatt acaccgggat tggtgctggt 360

gtgctcatag ttgcctacat ccaggtttca ttttggtgcc tggcagctgg aagacagata 420

cacaagatca ggcagaagtt ttttcatgct ataatgaatc aggagatagg ctggtttgat 480

gtgcatgacg ttggggagct caacacccgg ctcacagatg atgtttccaa aattaatgaa 540

ggaattggtg acaaaatcgg aatgttcttc caggcaatgg caacattttt tggtggtttt 600

ataataggat ttacccgtgg ctggaagcta acccttgtga ttttggccat cagccctgtt 660

cttggactgt cagctggtat ttgggcaaag atattgtctt catttactga taaggaactc 720

catgcttatg caaaagctgg agcagttgct gaagaagtct tagcagccat cagaactgtg 780

attgcgtttg gaggacaaaa gaaggaactt gaaaggtaca ataacaactt ggaagaagct 840

aaaaggctgg ggataaagaa agctatcacg gccaacatct ccatgggtgc agctttttctc 900

cttatctatg catcatatgc tctggcattc tggtatggga cttccttggt catctccaaa 960

gaatactcta ttggacaagt gctcactgtc ttcttttccg tgttaattgg agcattcagt 1020

gttggacagg catctccaaa tattgaagcc ttcgccaatg cacgaggagc agcttatgaa 1080

gtcttcaaaa taattgataa taagcccagt atagacagct ctcaaagag tgggcacaaa 1140

ccagacaaca tacaaggaaa tctggaattt aagaatattc acttcagtta cccatctcga 1200

aaagaagttc agatcttgaa gggcctcaat ctgaaggtga gagcggaca gacggtggcc 1260

ctggttggca acagtggctg tggaaaaagc acaactgtcc agctgatgca aaggctctac 1320

gacccccctag atggcatggt cagtatcgac ggacaggaca tcagaaccat caatgtgagg 1380

tatctgaggg agatcattgg tgtggtgagt caggaacctg tgctgtttgc caccacgatc 1440

gccgagaaca ttcgctatgg ccgagaagat gtcaccatgg atgagattga gaaagctgtc 1500

```
aaggaagcca atgcctatga cttcatcatg aaactgcccc accaatttga caccctggtt 1560

.ggtgagagag gggcgcacgt gagtggggga cagaaacaga gaatcgccat tgcccgggcc 1620

ctggtccgca atcccaagat ccttttgttg gacgaggcca cctcagccct ggatacagaa 1680

agtgaagctg tggttcaggc cgcactggat aaggctagag aaggccggac caccattgtg 1740

atagctcatc gcttgtctac cgttcgtaat gctgacgtca ttgctggttt tgatggtggt 1800

gtcattgtgg agcaaggaaa tcatgatgag ctcatgagag aaaagggcat ttacttcaaa 1860

cttgtcatga cacagacagc aggaaatgaa attgaattag gaaatgaagc ttgtaaatct 1920

aaggatgaaa ttgataattt agacatgtct tcaaaagatt caggatccag tctaataaga 1980

agaagatcaa ctcgcaaaag catctgtgga ccacatgacc aagacaggaa gcttagtacc 2040

aaagaggccc tggatgaaga tgtacctcca gcttcctttt ggcggatcct gaagttgaat 2100

tcaactgaat ggccttattt tgtggttggt atattctgtg ccataataaa tggaggctta 2160

cagccagcat ctccgtaat attttcaaaa gttgtagggg tttttacaaa tggtggcccc 2220

cctgaaaccc agcggcagaa cagcaacttg tttttccttgt tgtttctgat ccttgggatc 2280

atttctttca ttacattttt tcttcagggc ttcacatttg gcaaagctgg agagatcctc 2340

accaagcgac tccgatacat ggttttcaaa tccatgctga gacaggatgt gagctggttt 2400

gatgaccta aaaacaccac cggagcactg accaccaggc tcgccaacga tgctgctcaa 2460

gtgaaagggg ctacagggtc taggcttgct gtgattttcc agaacatagc aaatcttggg 2520

acaggaatca tcatatccct aatctatggc tggcaactaa cacttttact cttagcaatt 2580

gtacccatca ttgcgatagc tggagtggtt gaaatgaaaa tgttgtctgg acaagcactg 2640

aaagataaga aggaactaga aggttctgga aagattgcta cggaagcaat tgaaaacttc 2700

cgcactgttg tctctttgac tcgggagcag aagtttgaaa ccatgtatgc ccagagcttg 2760

cagataccat acagaaatgc gatgaagaaa gcacacgtgt ttgggatcac gttctccttc 2820

acccaggcca tgatgtattt ttcttatgct gcttgtttcc ggttcggtgc ctacttggtg 2880

acacaacaac tcatgacttt tgaaaatgtt ctgttagtat tctcagctat tgtctttggt 2940

gccatggcag tggggcaggt cagttcattc gctcctgact atgcgaaagc aacagtgtca 3000

gcatcccaca tcatcaggat cattgagaaa accccgaga ttgacagcta cagcacgcaa 3060

ggcctaaagc cgaatatgtt ggaaggaaat gtgcaattta gtggagtcgt gttcaactat 3120

cccaccgac ccagcatccc agtgcttcag gggctgagcc ttgaggtgaa gaagggccag 3180

acgctggccc tggtgggcag cagtggctgc gggaagagca cagtggtcca gctgctcgag 3240
```

36

```
cgcttctacg accccatggc tggatcagtg tttctagatg gcaaagaaat aaagcaactg 3300

aatgtccagt ggctccgagc acagctgggc attgtgtccc aagagcccat tctctttgac 3360

tgcagcatcg cagagaacat tgcctacgga gacaacagcc gggtcgtgtc ttatgaggag 3420

attgtgaggg cagccaagga ggccaacatc caccagttca tcgactcgct acctgataaa 3480

tacaacacca gagtaggaga caaaggcact cagctgtcgg gtgggcagaa gcagcgcatc 3540

gccatcgcac gcgccctcgt cagacagcct cacattttac ttctggacga agcaacatca 3600

gctctggata cagaaagtga aaaggttgtc caggaagcgc tggacaaagc cagggaaggc 3660

cgcacctgca ttgtgatcgc tcaccgcctg tccaccatcc agaacgcgga cttgatcgtg 3720

gtgattcaga acggcaaggt caaggagcac ggcacccacc agcagctgct ggcgcagaag 3780

ggcatctact tctcaatggt cagtgtgcag gctggagcaa agcgctcatg aactgtgacc 3840

atgtaagatg ttaagtattt ttattgtttg tattcatata tggtgtttaa tccaagtcaa 3900

aaggaaaaca cttactaaaa tagccagtta tctattttct gccacagtgg aaagcattta 3960

gtttggttta gagtcttcag aggctttgta attaaaaaaa caaaaataga tacagcatca 4020

aatggagatt aatgctttaa aatgcactat aaaatttata aaagggttaa aagtgaatgt 4080

ttgataatat atacttttat ttatactttc tcatttgtaa ctataactga tttctgctta 4140

acaaattatg tatgtatcaa aaattactga aatgtttgta taaagtatat atagtgaaac 4200

tgagcattca tattttgag ttattttgct caaatgcatg cgaaattata tattgtccca 4260

actgggatat tgtacataat tttagccttt aaaaaacagt ccattactgg ggggaggggg 4320

catcactcta tgggcaaagt gttactcaga catgggcacc tgagttcaga tccctaccac 4380

ctaagtaagc agacaaggtg tggtgttttt gtaatgccag tgctagaggc agaaaagaca 4440

gatcctgcag gctcagtggc tggccaaaca gcctagccaa catagcgcgt tccaggttca 4500

gtgagaaaac ttgtctcaaa aatcagaggg aaaagcaaat gaggtgtcag ccatgtgcac 4560

tcatgcaaat gccatacatg cagaagtatg tgcacacaca cgcacacatt aaccaacgac 4620

tagcaaggaa aatgaaggtg gataagaggg gtgggactgg gacaaaggag ggtacctgga 4680

tgaatatgac tgaaggacgt tatgtacaca tatgaaaacg tcgtactgaa actcactaca 4740

atgtatactt aatatattgc taataaaata ttttaaaag aaaaaaat            4788
```

<210> 8

<211> 1276

<212> PRT

<213> MOUSE MDR-3

<400> 8

Met Glu Leu Glu Glu Asp Leu Lys Gly Arg Ala Asp Lys Asn Phe Ser

 1   5   10   15

Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys Pro Ala

             20   25   30

Val Ser Val Leu Thr Met Phe Arg Tyr Ala Gly Trp Leu Asp Arg Leu

         35   40   45

Tyr Met Leu Val Gly Thr Leu Ala Ala Ile Ile His Gly Val Ala Leu

     50   55   60

Pro Leu Met Met Leu Ile Phe Gly Asp Met Thr Asp Ser Phe Ala Ser

 65   70   75   80

Val Gly Asn Val Ser Lys Asn Ser Thr Asn Met Ser Glu Ala Asp Lys

             85   90   95

Arg Ala Met Phe Ala Lys Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr

             100   105   110

Tyr Tyr Thr Gly Ile Gly Ala Gly Val Leu Ile Val Ala Tyr Ile Gln

         115   120   125

Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile His Lys Ile Arg

        130   135   140

Gln Lys Phe Phe His Ala Ile Met Asn Gln Glu Ile Gly Trp Phe Asp
145   150   155   160

Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr Asp Asp Val Ser
                165   170   175

Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile Gly Met Phe Phe Gln Ala
                180   185   190

Met Ala Thr Phe Phe Gly Gly Phe Ile Ile Gly Phe Thr Arg Gly Trp
            195   200   205

Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val Leu Gly Leu Ser
            210   215   220

Ala Gly Ile Trp Ala Lys Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu
225   230   235   240

His Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu Val Leu Ala Ala
                245   250   255

Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg
            260   265   270

Tyr Asn Asn Asn Leu Glu Glu Ala Lys Arg Leu Gly Ile Lys Lys Ala
            275   280   285

                                39

Ile Thr Ala Asn Ile Ser Met Gly Ala Ala Phe Leu Leu Ile Tyr Ala
    290   295   300

Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Ser Leu Val Ile Ser Lys
305   310   315   320

Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe Ser Val Leu Ile
                325   330   335

Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Asn Ile Glu Ala Phe Ala
                340   345   350

Asn Ala Arg Gly Ala Ala Tyr Glu Val Phe Lys Ile Ile Asp Asn Lys
        355   360   365

Pro Ser Ile Asp Ser Phe Ser Lys Ser Gly His Lys Pro Asp Asn Ile
    370   375   380

Gln Gly Asn Leu Glu Phe Lys Asn Ile His Phe Ser Tyr Pro Ser Arg
385   390   395   400

Lys Glu Val Gln Ile Leu Lys Gly Leu Asn Leu Lys Val Lys Ser Gly
                405   410   415

Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr
                420   425   430

Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Leu Asp Gly Met Val Ser
        435   440   445

40

Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg Tyr Leu Arg Glu
    450   455   460

Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe Ala Thr Thr Ile
465   470   475   480

Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asp Val Thr Met Asp Glu Ile
                485   490   495

Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu
            500   505   510

Pro His Gln Phe Asp Thr Leu Val Gly Glu Arg Gly Ala His Val Ser
            515   520   525

Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn
    530   535   540

Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu
545   550   555   560

Ser Glu Ala Val Val Gln Ala Ala Leu Asp Lys Ala Arg Glu Gly Arg
            565   570   575

Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val Arg Asn Ala Asp
            580   585   590

Val Ile Ala Gly Phe Asp Gly Gly Val Ile Val Glu Gln Gly Asn His

41

                595   600   605

Asp Glu Leu Met Arg Glu Lys Gly Ile Tyr Phe Lys Leu Val Met Thr
        610   615   620

Gln Thr Ala Gly Asn Glu Ile Glu Leu Gly Asn Glu Ala Cys Lys Ser
625   630   635   640

Lys Asp Glu Ile Asp Asn Leu Asp Met Ser Ser Lys Asp Ser Gly Ser
                645   650   655

Ser Leu Ile Arg Arg Arg Ser Thr Arg Lys Ser Ile Cys Gly Pro His
            660   665   670

Asp Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu Asp Glu Asp Val
        675   680   685

Pro Pro Ala Ser Phe Trp Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp
        690   695   700

Pro Tyr Phe Val Val Gly Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu
705   710   715   720

Gln Pro Ala Phe Ser Val Ile Phe Ser Lys Val Val Gly Val Phe Thr
                725   730   735

Asn Gly Gly Pro Pro Glu Thr Gln Arg Gln Asn Ser Asn Leu Phe Ser
            740   745   750

42

Leu Leu Phe Leu Ile Leu Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu
        755   760   765

Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu
        770   775   780

Arg Tyr Met Val Phe Lys Ser Met Leu Arg Gln Asp Val Ser Trp Phe
785   790   795   800

Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn
            805   810   815

Asp Ala Ala Gln Val Lys Gly Ala Thr Gly Ser Arg Leu Ala Val Ile
            820   825   830

Phe Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile
        835   840   845

Tyr Gly Trp Gln Leu Thr Leu Leu Leu Leu Ala Ile Val Pro Ile Ile
        850   855   860

Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser Gly Gln Ala Leu
865   870   875   880

Lys Asp Lys Lys Glu Leu Glu Gly Ser Gly Lys Ile Ala Thr Glu Ala
            885   890   895

Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Arg Glu Gln Lys Phe
        900   905   910

43

                    1060   1065   1070

Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp Pro Met Ala Gly
        1075   1080   1085

Ser Val Phe Leu Asp Gly Lys Glu Ile Lys Gln Leu Asn Val Gln Trp
    1090   1095   1100

Leu Arg Ala Gln Leu Gly Ile Val Ser Gln Glu Pro Ile Leu Phe Asp
1105   1110   1115   1120

Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn Ser Arg Val Val
            1125   1130   1135

Ser Tyr Glu Glu Ile Val Arg Ala Ala Lys Glu Ala Asn Ile His Gln
            1140   1145   1150

Phe Ile Asp Ser Leu Pro Asp Lys Tyr Asn Thr Arg Val Gly Asp Lys
        1155   1160   1165

Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg
    1170   1175   1180

Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu Ala Thr Ser
1185   1190   1195   1200

Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala Leu Asp Lys
        1205   1210   1215

                                  45

Glu Thr Met Tyr Ala Gln Ser Leu Gln Ile Pro Tyr Arg Asn Ala Met
        915   920   925

Lys Lys Ala His Val Phe Gly Ile Thr Phe Ser Phe Thr Gln Ala Met
        930   935   940

Met Tyr Phe Ser Tyr Ala Ala Cys Phe Arg Phe Gly Ala Tyr Leu Val
945   950   955   960

Thr Gln Gln Leu Met Thr Phe Glu Asn Val Leu Leu Val Phe Ser Ala
                965   970   975

Ile Val Phe Gly Ala Met Ala Val Gly Gln Val Ser Ser Phe Ala Pro
                980   985   990

Asp Tyr Ala Lys Ala Thr Val Ser Ala Ser His Ile Ile Arg Ile Ile
            995   1000   1005

Glu Lys Thr Pro Glu Ile Asp Ser Tyr Ser Thr Gln Gly Leu Lys Pro
        1010   1015   1020

Asn Met Leu Glu Gly Asn Val Gln Phe Ser Gly Val Val Phe Asn Tyr
1025   1030   1035   1040

Pro Thr Arg Pro Ser Ile Pro Val Leu Gln Gly Leu Ser Leu Glu Val
            1045   1050   1055

Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser Gly Cys Gly Lys

44

Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg Leu Ser Thr

        1220   1225   1230

Ile Gln Asn Ala Asp Leu Ile Val Val Ile Gln Asn Gly Lys Val Lys

      1235   1240   1245

Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe

   1250   1255   1260

Ser Met Val Ser Val Gln Ala Gly Ala Lys Arg Ser

1265   1270   1275

46